TAKAHAMA Takayuki

Researcher Information

Degree

• M.D., Ph. D.（2018/03 Kindai University）

J-Global ID

• 201401098802467069

Research Areas

• Life sciences / Tumor diagnostics and therapeutics

Academic & Professional Experience

• 2022/04 - Today  Kindai UniversityKindai University Hospotal
• 2021/04 - 2022/03  Kindai UniversityDepartment of medical oncology
• 2020/04 - 2021/03  Kindai UniversityNara Hospital Kindai University
• 2019/04 - 2020/03  Kindai UniversityNara Hospital Kindai University
• 2015/04 - 2019/03  Kindai UniversityFaculty of Medicine
• 2013/04 - 2015/03  Kindai UniversityKindai University Hospotal
• 2012/04 - 2013/03  Kagawa University内分泌代謝血液免疫呼吸器内科学
• 2011/04 - 2012/03  Kagawa prefectural central hospitalRespiratory medicine
• 2009/04 - 2011/03  Kagawa prefectural central hospital

Education

• 2015/04 - 2018/03  Kindai University  Faculty of Medicine  大学院医学研究科
• 2003/04 - 2009/03  Kagawa University  Faculty of Medicine  School of Medicine

Association Memberships

• THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER   THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY   THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES   THE JAPAN LUNG CANCER SOCIETY   THE JAPANESE RESPIRATORY SOCIETY   THE JAPANESE CANCER ASSOCIATION   日本臨床腫瘍学会   THE JAPANESE SOCIETY OF INTERNAL MEDICINE   

Published Papers

• Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

  Hidetoshi Hayashi; Kenji Chamoto; Ryusuke Hatae; Takashi Kurosaki; Yosuke Togashi; Kazuya Fukuoka; Megumi Goto; Yasutaka Chiba; Shuta Tomida; Takayo Ota; Koji Haratani; Takayuki Takahama; Junko Tanizaki; Takeshi Yoshida; Tsutomu Iwasa; Kaoru Tanaka; Masayuki Takeda; Tomoko Hirano; Hironori Yoshida; Hiroaki Ozasa; Yuichi Sakamori; Kazuko Sakai; Keiko Higuchi; Hitoshi Uga; Chihiro Suminaka; Toyohiro Hirai; Kazuto Nishio; Kazuhiko Nakagawa; Tasuku Honjo

  Journal of Clinical Investigation American Society for Clinical Investigation 134 (7) 2024/04 

  BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4 in plasma of patients with advanced NSCLC before PD-1/PD-L1 blockade. A prospective biomarker-finding trial (cohort A) included 50 previously treated patients who received nivolumab. A retrospective observational study was performed for patients treated with any PD-1/PD-L1 blockade therapy (cohorts B and C), cytotoxic chemotherapy (cohort D), or targeted therapy (cohort E). Plasma samples from all patients were assayed for soluble immune-checkpoint molecules with a highly sensitive chemiluminescence-based assay.RESULTSNonresponsiveness to PD-1/PD-L1 blockade therapy was associated with higher concentrations of these soluble immune factors among patients with immune-reactive (hot) tumors. Such an association was not apparent for patients treated with cytotoxic chemotherapy or targeted therapy. Integrative analysis of tumor size, PD-L1 expression in tumor tissue (tPD-L1), and gene expression in tumor tissue and peripheral CD8+ T cells revealed that high concentrations of the 3 soluble immune factors were associated with hyper or terminal exhaustion of antitumor immunity. The combination of soluble PD-L1 (sPD-L1) and sCTLA-4 efficiently discriminated responsiveness to PD-1/PD-L1 blockade among patients with immune-reactive tumors.CONCLUSIONCombinations of soluble immune factors might be able to identify patients unlikely to respond to PD-1/PD-L1 blockade as a result of terminal exhaustion of antitumor immunity. Our data suggest that such a combination better predicts, along with tPD-L1, for the response of patients with NSCLC.TRIAL REGISTRATIONUMIN000019674.FUNDINGThis study was funded by Ono Pharmaceutical Co. Ltd. and Sysmex Corporation.
• Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.

  Daisuke Hazama; Kenji Nakahama; Hiroaki Kodama; Akito Miyazaki; Koichi Azuma; Yosuke Kawashima; Yuki Sato; Kentaro Ito; Yoshimasa Shiraishi; Keita Miura; Takayuki Takahama; Satoshi Oizumi; Yoshinobu Namba; Satoshi Ikeda; Hiroshige Yoshioka; Asuka Tsuya; Yuichiro Yasuda; Yoshiki Negi; Ayako Hara; Michihito Toda; Motoko Tachihara

  JTO clinical and research reports 5 (1) 100613 - 100613 2024/01 

  INTRODUCTION: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studies. Nevertheless, because these studies included a small number of patients owing to disease rarity, larger studies are needed to evaluate the effectiveness and safety of ICI-based therapy for PSC. METHODS: This multicenter retrospective study evaluated patients with ICI-naive advanced or metastatic PSC who were treated with ICI-based therapy at 25 hospitals in Japan. RESULTS: A total of 124 patients were evaluated. The overall response rate, median progression-free survival (PFS), and median overall survival (OS) were 59.0%, 10.5 months, and 32.8 months, respectively. The PFS and OS rates at 24 months were 35.3% and 51.5%, respectively. Programmed death-ligand 1 expression, concomitant chemotherapy, and the treatment line were not significantly associated with PFS or OS. Immune-related adverse events (irAEs) were observed in 70 patients (56.5%), including 30 (24.2%) with grade 3 to 5 events. Patients with mild irAEs (grades 1-2) had longer PFS and OS than did those with severe (grades 3-5) or no irAEs. In a multivariate analysis, any-grade irAEs and the absence of liver metastases were independently associated with PFS, whereas any-grade irAEs and Eastern Cooperative Oncology Group performance status less than or equal to 1 were independently associated with OS. CONCLUSIONS: ICI-based therapy was found to have promising effectiveness in patients with advanced or metastatic PSC, regardless of programmed death-ligand 1 expression, concomitant chemotherapy, or treatment line.
• Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

  Tomohiro Sakamoto; Taichi Matsubara; Takayuki Takahama; Toshihide Yokoyama; Atsushi Nakamura; Takaaki Tokito; Tatsuro Okamoto; Hiroaki Akamatsu; Masahide Oki; Yuki Sato; Kazunori Tobino; Satoshi Ikeda; Masahide Mori; Chihiro Mimura; Ken Maeno; Satoru Miura; Toshiyuki Harada; Kunihiro Nishimura; Manabu Hiraoka; Hirotsugu Kenmotsu; Junya Fujimoto; Mototsugu Shimokawa; Nobuyuki Yamamoto; Kazuhiko Nakagawa

  JAMA network open 6 (12) e2347700  2023/12 [Refereed]
   

  IMPORTANCE: Biomarker testing for driver mutations is essential for selecting appropriate non-small cell lung cancer (NSCLC) treatment but is insufficient. OBJECTIVE: To investigate the status of biomarker testing and drug therapy for NSCLC in Japan for identifying problems in treatment. DESIGN, SETTING, AND PARTICIPANTS: The REVEAL cohort study included retrospective data collection and prospective follow-up from 29 institutions across Japan. Of 1500 patients diagnosed with advanced or recurrent NSCLC between January 1 and March 18, 2021, 1479 were eligible. Cases recognized at the wrong clinical stage (n = 12), diagnosed outside the study period (n = 6), not treated according to eligibility criteria before recurrence (n = 2), and with deficient consent acquisition procedure (n = 1) were excluded. MAIN OUTCOMES AND MEASURES: The primary end point was the biomarker testing status. Treatment-related factors were examined. RESULTS: Among the 1479 patients included in the analysis, the median age was 72 (range, 30-95) years; 1013 (68.5%) were men; 1161 (78.5%) had an Eastern Cooperative Oncology Group performance status 0 or 1; 1097 (74.2%) were current or past smokers; and 947 (64.0%) had adenocarcinoma. Biomarker status was confirmed in 1273 patients (86.1%). Multigene testing was performed in 705 cases (47.7%); single-gene testing, in 847 (57.3%); and both, in 279 (18.9%). Biomarker testing was performed for EGFR in 1245 cases (84.2%); ALK, in 1165 (78.8%); ROS1, in 1077 (72.8%); BRAF, in 803 (54.3%); and MET, in 805 (54.4%). Positivity rates among 898 adenocarcinoma cases included 305 (34.0%) for EGFR, 29 (3.2%) for ALK, 19 (2.1%) for ROS1, 11 (1.2%) for BRAF, and 14 (1.6%) for MET. Positivity rates among 375 nonadenocarcinoma cases were 14 (3.7%) for EGFR, 6 (1.6%) for ALK, 1 (0.3%) for ROS1, 3 (0.8%) for BRAF, and 8 (2.1%) for MET. Poor physical status, squamous cell carcinoma, and other comorbidities were associated with hampered multigene testing. Targeted therapy was received as first-line treatment by 263 of 278 cases (94.6%) positive for EGFR, 25 of 32 (78.1%) positive for ALK, 15 of 24 (62.5%) positive for ROS1, 9 of 12 (75.0%) positive for BRAF, and 12 of 19 (63.2%) positive for MET. Median overall survival of patients with positive findings for driver gene alteration and who received targeted therapy was 24.3 (95% CI, not reported) months; with positive findings for driver gene alteration and who did not receive targeted therapy, 15.2 (95% CI, 7.7 to not reported) months; and with negative findings for driver gene alteration, 11.0 (95% CI, 10.0-12.5) months. Multigene testing for nonadenocarcinomas and adenocarcinomas accounted for 705 (47.7%) of all NSCLC cases. CONCLUSIONS AND RELEVANCE: These findings suggest that multigene testing has not been sufficiently implemented in Japan and should be considered prospectively, even in nonadenocarcinomas, to avoid missing rare driver gene alterations.
• A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

  Yasushi Goto; Hirotsugu Kenmotsu; Motohiro Tamiya; Shuji Murakami; Takayasu Kurata; Noriko Yanagitani; Hirokazu Taniguchi; Shoichi Kuyama; Junichi Shimizu; Toshihide Yokoyama; Naoko Shimada; Tadashi Maeda; Akihiro Tamiya; Ayumi Uchiyama; Kazuyoshi Imaizumi; Takayuki Takahama; Terufumi Kato; Hidetoshi Hayashi; Naoko Shiraiwa; Shigeyuki Toyoizumi; Hironori Kikkawa; Despina Thomaidou; Makoto Nishio

  JTO Clinical and Research Reports Elsevier BV 4 (5) 100508 - 100508 2666-3643 2023/05 

  INTRODUCTION: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. METHODS: We retrospectively analyzed patients with advanced ALK+ NSCLC previously treated with 1L alectinib at multiple sites in Japan. Primary objectives were to collect patient demographics at baseline and estimate time to treatment failure (TTF) with second-line (2L) or third-line (3L) or later line (≥3L) lorlatinib treatment. Secondary objectives included objective response rate (ORR) with lorlatinib, reason for discontinuation and time to last treatment failure with lorlatinib, TTF and ORR of alectinib, and combined TTF. RESULTS: Among the 51 patients included in the study, 29 (56.9%) received 2L and 22 (43.1%) received ≥3L lorlatinib treatment. At lorlatinib initiation, brain metastases were reported in 25 patients (49.0%), and 32 (62.7%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Median TTF with lorlatinib was 11.1 months (95% confidence interval [CI]: 4.6-13.8) in any line, 10.8 months (95% CI: 3.9-13.8) in 2L, and 11.5 months (95% CI: 2.9-not reached) in ≥3L. Median TTF was 11.5 months (95% CI: 3.9-not reached) in patients with brain metastases at lorlatinib initiation and 9.9 months (95% CI: 4.3-13.8) in patients without brain metastases. ORR was 35.7% with any-line lorlatinib treatment. CONCLUSIONS: Patient characteristics and efficacy were comparable with previous reports when lorlatinib was given after 1L alectinib in patients with ALK+ NSCLC.
• Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma

  Yasuo Otsuka; Yoriaki Komeda; Masayuki Takeda; Takayuki Takahama; Masashi Kono; Mamoru Takenaka; Satoru Hagiwara; Naoshi Nishida; Hiroshi Kashida; Masatoshi Kudo

  Case Reports in Medicine Hindawi Limited 2023 1 - 4 1687-9627 2023/02 

  A 76-year-old woman presented with lower abdominal pain and nausea and was referred to the gastroenterology department in our institution. Previous contrast-enhanced computed tomography (CE-CT) for follow-up after breast cancer surgery had indicated a soft tissue mass below the right diaphragm, which was considered a benign change. CE-CT performed at the first visit to our department revealed further thickening of the soft tissue mass with extension to the liver surface. In addition, ascites and nodules were observed in the abdominal cavity. Histopathological examination of a biopsy specimen revealed peritoneal invasion of atypical epithelioid cells with trabecular and glandular patterns. The tumor cells were positive for AE1/AE2, calretinin, WT-1, D2-40, HEG1, EMA, BAP1, and MTAP and negative for carcinoembryonic antigen, MOC-31, Ber-Ep4, ER, PgR, TTF-1, claudin 4, and desmin. A diagnosis of epithelioid mesothelioma was made. The patient received chemotherapy with cisplatin (75 mg/m2) and pemetrexed (500 mg/m2). After six courses of combined chemotherapy, pemetrexed was administered as a single agent. At the time of writing this report, she was undergoing over the 30th course of chemotherapy without any significant side effects. Diffuse malignant peritoneal mesothelioma is a rare, fatal, and progressive disease. Our patient achieved long-term survival of more than 5 years with maintenance therapy using single-agent pemetrexed.
• Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain

  Fujita, Y.; Matsuoka, H.; Chiba, Y.; Tsurutani, J.; Yoshida, T.; Sakai, K.; Nakura, M.; Sakamoto, R.; Makimura, C.; Ohtake, Y.; Tanaka, K.; Hayashi, H.; Takeda, M.; Okuno, T.; Takegawa, N.; Haratani, K.; Takahama, T.; Tanizaki, J.; Koyama, A.; Nishio, K.; Nakagawa, K.

  Oncology Letters 26 (2) 355 - 355 1792-1082 2023 

  There have been few studies on predictive biomarkers that may be useful to select the most suitable opioids to optimize therapeutic efficacy in individual patients with cancer pain. We recently investigated the efficacy of morphine and oxycodone using single nucleotide polymorphisms (SNPs) of the catechol-O-methyltransferase (COMT) rs4680 gene as a biomarker (RELIEF study). To explore additional biomarkers that may enable the selection of an appropriate opioid for individual patients with cancer pain, three SNPs were examined: C-C motif chemokine ligand 11 (CCL11; rs17809012), histamine N-methyltransferase (HNMT; rs1050891) and transient receptor potential V1 (TRPV1; rs222749), which were screened from 74 pain-related SNPs. These SNPs, which were identified as being significantly associated with the analgesic effect of morphine, were then used to genotype the 135 patients in the RELIEF study who had been randomized into a morphine group (n=69) or an oxycodone group (n=66). The present study then assessed whether the SNPs could also be used as selective biomarkers to predict which opioid(s) might be the most suitable to provide pain relief for patients with cancer. Oxycodone tended to provide superior analgesic effects over morphine in patients carrying the genotype AA for the CCL11 rs17809012 SNP (P=0.012 for interaction), suggesting that it could serve as a potential biomarker for personalized analgesic therapy for patients suffering with cancer pain.
• Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.

  Kana Fujimoto; Satomi Watanabe; Yuto Yasuda; Emi Date; Yasuhiro Kawabata; Hiroaki Kanemura; Takayuki Takahama; Kimio Yonesaka; Norishige Iizuka; Ken-Ichi Takahashi; Osamu Kawakami; Tomohiro Ozaki; Kazuhiko Nakagawa

  Thoracic cancer 14 (2) 214 - 217 2023/01 

  High-grade fetal lung adenocarcinoma (H-FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56-year-old man with stage IV H-FLAC who was successfully treated with carboplatin plus nab-paclitaxel in combination with atezolizumab. In addition, the tumor was found to be positive for amplification of the human epidermal growth factor receptor 2 gene.
• Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review

  Tsukamoto, S.; Takahama, T.; Mavrogenis, A.F.; Tanaka, Y.; Tanaka, Y.; Errani, C.

  Musculoskeletal Surgery 107 (1) 2035-5114 2023
• 進行・再発非小細胞肺癌のバイオマーカー検査と標的治療に関する実態調査プロジェクト WJOG1542IL(REVEAL)

  阪本 智宏; 松原 太一; 高濱 隆幸; 横山 俊秀; 中村 敦; 時任 高章; 岡本 龍郎; 赤松 弘朗; 沖 昌英; 佐藤 悠城; 飛野 和則; 西村 邦裕; 平岡 学; 釼持 広知; 藤本 淳也; 下川 元継; 山本 信之; 中川 和彦

  肺癌 (NPO)日本肺癌学会 62 (6) 491 - 491 0386-9628 2022/11
• がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定

  米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人

  肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
• がん遺伝子パネル検査FoundationOneによる肺癌の遺伝子変異の測定

  米阪 仁雄; 高濱 隆幸; 黒崎 隆; 川中 雄介; 金村 宙昌; 磯本 晃佑; 鈴木 慎一郎; 三谷 誠一郎; 中川 和彦; 白石 直樹; 小田 いつき; 西郷 和真; 池川 敦子; 福岡 和也; 武田 真幸; 西尾 和人

  肺癌 (NPO)日本肺癌学会 62 (5) 439 - 439 0386-9628 2022/10
• The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.

  Hiroaki Kanemura; Hidetoshi Hayashi; Shuta Tomida; Junko Tanizaki; Shinichiro Suzuki; Yusuke Kawanaka; Asuka Tsuya; Yasushi Fukuda; Hiroyasu Kaneda; Keita Kudo; Takayuki Takahama; Ryosuke Imai; Koji Haratani; Yasutaka Chiba; Tomoyuki Otani; Akihiko Ito; Kazuko Sakai; Kazuto Nishio; Kazuhiko Nakagawa

  JTO clinical and research reports 3 (8) 100373 - 100373 2022/08 

  Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. Methods: A total of 135 patients with ES-SCLC treated with chemotherapy either alone (chemo-cohort, n = 71) or together with an ICI (ICI combo-cohort, n = 64) was included in this retrospective study. Tumors were classified pathologically as inflamed or noninflamed on the basis of programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density. Immune-related gene expression profiling was performed, and predicted neoantigen load was determined by whole-exome sequencing. Results: Among patients in the ICI combo-cohort, median progression-free survival was 10.8 and 5.1 months for those with inflamed (n = 7) or noninflamed (n = 56) tumors, respectively (log-rank test p = 0.002; hazard ratio of 0.26). Among the 89 patients with immune-related gene expression profiling data available, inflamed tumors had a higher T cell-inflamed GEP score than did noninflamed tumors (-0.18 versus -0.58, p < 0.001). The 12-month progression-free survival rate was 16.1% and 0% for patients in the ICI combo-cohort harboring tumors with a high (n = 26) or low (n = 18) frameshift neoantigen load, respectively. A high-frameshift neoantigen load was associated with up-regulation of gene signatures related to antigen presentation and costimulatory signaling. A durable clinical benefit of ICI therapy was observed only in patients with inflamed tumors and a high-frameshift neoantigen load. Conclusions: Expression of programmed death-ligand 1, CD8+ T cell infiltration, and a high-frameshift neoantigen load are associated with clinical benefit of ICI therapy in ES-SCLC. Clinical trial registration: UMIN000041056.
• 最新のがん 近畿大学病院ゲノム医療センターの活動とがんゲノム医療の展望

  高濱 隆幸; 米阪 仁雄; 白石 直樹; 小田 いつき; 池川 敦子; 西郷 和真; 福岡 和也; 中川 和彦

  近畿大学医学雑誌 近畿大学医学会 47 (1-2) 19 - 25 0385-8367 2022/06 

  近年、次世代シークエンサー(NGS)の臨床応用が進み、がんに生じた遺伝子変化を網羅的に解析することが可能となった。包括的がんゲノムプロファイリング(CGP)検査を実施することで、がん化に関わる原因遺伝子が明らかになると同時に、治療の選択肢が増え、恩恵を受ける症例が出てきている。近畿大学病院ゲノム医療センターでは、2019年に日本においてCGP検査が保険適応を受けて以降、がん関連遺伝子検査がスムーズに進むよう業務を行っている。エキスパートパネルの運営を通して、患者や主治医への適切な遺伝子解析結果を届けることを目標とし、また二次的所見への対応などを行ってきた。本稿では、CGP検査の現状について概説し、特に課題の多い出口戦略について、治療への到達率を高めるために必要なことは何か考察をしたい。(著者抄録)
• A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC.

  Daichi Fujimoto; Satoru Miura; Kenichi Yoshimura; Kazushige Wakuda; Yuko Oya; Koji Haratani; Shoichi Itoh; Takehiro Uemura; Ryotaro Morinaga; Takayuki Takahama; Kazuhisa Nakashima; Motoko Tachihara; Go Saito; Junko Tanizaki; Kohei Otsubo; Satoshi Ikeda; Hirotaka Matsumoto; Satoshi Hara; Akito Hata; Takeshi Masuda; Nobuyuki Yamamoto

  JTO clinical and research reports 3 (2) 100265 - 100265 2666-3643 2022/02 

  Introduction: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance status (≥2), has not been fully elucidated. We investigated the real-world effectiveness and safety of this combination therapy in these populations. Methods: This multicenter retrospective study evaluated patients who are chemo-naïve with advanced NSCLC who received a combination of platinum, pemetrexed, and pembrolizumab between December 2018 and June 2019. This was an updated prespecified secondary analysis with the primary objective of investigating the safety and effectiveness in this cohort. Results: Overall, 299 patients were included. Multivariate analysis identified performance status (0-1) and programmed death-ligand 1 tumor proportion score (≥50%) as significant independent predictors of progression-free survival (p = 0.007, and p = 0.003, respectively). The incidence of severe adverse events (AEs) was higher in the elderly and those with poor performance status than in their younger and good performance status counterparts. A total of 71 patients developed AEs that led to treatment discontinuation, and AE-related treatment discontinuation occurred at a significantly higher rate in older patients (median [range]) (70 [46-82] y) than in younger patients (68 [31-84] y) (p <0.001). Conclusions: Combination treatment with pembrolizumab plus chemotherapy had low real-world effectiveness for poor performance status patients. Severe AEs occurred at a higher rate in the elderly and poor performance status patients, and the AE-related treatment discontinuation rate increased with age. Physicians should be cautious about using this regimen, especially in the elderly and poor performance status patients.
• Role of debulking surgery in combination with immune therapy: A successfully treated case of locally advanced mucosal melanoma.

  Takahiro Kimura; Takayuki Takahama; Tomoko Wakasa; Shiori Adachi; Yusaku Akashi; Takao Tamura; Katsunari Yane

  Molecular and clinical oncology 16 (1) 2 - 2 2022/01 

  Immune checkpoint inhibitors (ICIs) have markedly changed the treatment landscape for melanoma; however, their efficacy and applications are currently limited and medical requirements remain unmet. The present case study reports on a 85-year-old female patient who visited our outpatient clinic with a 1-month history of a buccal mucosa mass and was diagnosed with locally advanced mucosal melanoma of the head and neck. The patient's tumor progressed right after the administration of nivolumab, compromising oral intake. Palliative debulking surgery was performed. Subsequently, the other part of the melanoma on the hard palate slightly decreased in size without forming new lesions for more than one year after surgery. The present case exemplifies that tumor volume reduction surgery may increase the response to ICI and may prolong the duration of response. This combination therapy may be more effective in patients whose tumors increase in size after administration of ICIs or whose tumor is already large at the beginning of treatment. The combination of ICIs and debulking surgery may become an important treatment option in the future for locally advanced mucosal melanoma.
• Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial

  Yoshinori Imamura; Kaoru Tanaka; Naomi Kiyota; Hidetoshi Hayashi; Ichiro Ota; Akihito Arai; Shigemichi Iwae; Shujiro Minami; Katsunari Yane; Tomoko Yamazaki; Yoshiaki Nagatani; Masanori Toyoda; Takayuki Takahama; Kazuko Sakai; Kazuto Nishio; Naoki Otsuki; Ken-ichi Nibu; Hironobu Minami

  Medical Oncology Springer Science and Business Media LLC 38 (11) 128 - 128 1357-0560 2021/11 

  The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination in the first-line setting. Eligibility criteria were recurrent and/or metastatic NSCHNC; progressive disease within the last 6 months; no prior systemic therapy; and ECOG performance status of 0-1. Patients received docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles. The primary endpoint was confirmed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events. Next-generation sequencing (NGS) was performed using the Ion AmpliSeq Cancer Hotspot Panel v2. Twenty-three patients were enrolled from November 2012 to October 2016, of whom 8 were male. Median age was 57 years. Ninety-six percent of cases were metastatic. Among 22 evaluable patients, confirmed ORR was 45% (95% confidential interval 24-68%). With a median follow-up period of 18.8 months, median PFS and OS were 6.7 and 20.1 months, respectively. Grade 3/4 adverse events included febrile neutropenia (39%) and anemia (22%). No treatment-related deaths were observed. NGS analysis revealed potential treatment targets, including ERBB2, KIT, and ALK. The docetaxel and cisplatin combination regimen can be considered a new treatment option in recurrent and/or metastatic NSCHNC, although primary prophylaxis for febrile neutropenia should be considered. Diverse genomic alterations may lead novel treatment options.This trial was registered with the UMIN Clinical Trials Registry as UMIN000008333 on [September 1st, 2012].
• Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis

  Kazuko Sakai; Toshiharu Sakurai; Marco A. De Velasco; Tomoyuki Nagai; Takaaki Chikugo; Kazuomi Ueshima; Yurie Kura; Takayuki Takahama; Hidetoshi Hayashi; Kazuhiko Nakagawa; Masatoshi Kudo; Kazuto Nishio

  Frontiers in Oncology Frontiers Media {SA} 11 763468 - 763468 2234-943X 2021/10 

  Immune checkpoint inhibitors (ICIs) have become the standard of care for several cancers. However, ICI therapy has also been associated with various immune-related adverse events (irAEs). Clinical manifestations of immune-related colitis resemble those of inflammatory bowel diseases such as ulcerative colitis (UC). The composition of the bowel microflora is thought to influence the development of inflammatory bowel disease and irAE colitis. We profiled the gene expressions and microbe compositions of colonic mucosa from patients with solid cancers receiving anti-PD-L1 antibody treatment; we then compared the expression profiles associated with irAE colitis with those associated with UC. The pathway enrichment analysis revealed functional similarities between inflamed regions of irAE colitis and UC. The common enriched pathways included leukocyte extravasation and immune responses, whereas non-inflamed mucosa from patients with irAE colitis was distinct from patients with UC and was characterized by the recruitment of immune cells. A similarity between the microbiota profiles was also identified. A decreased abundance of Bacteroides species was observed in inflamed regions from both irAE colitis and UC based on a microbiota composition analysis of 16S rDNA sequencing. Pathways associated with molecule transport systems, including fatty acids, were enriched in inflamed and non-inflamed irAE colitis and inflamed UC, similar to Piphillin-inferred KEGG pathways. While UC is characterized by local regions of inflammation, ICI treatment extends to non-inflammatory regions of the colonial mucosa where immune cells are reconstituted. This analysis of the similarity and heterogeneity of irAE colitis and UC provides important information for the management of irAE colitis.
• P55.03 Results of The First Survey Using EORTC QLQ INFO25 on Information Acquisition and Satisfaction of Lung Cancer Patients in Japan

  T. Takahama; H. Shimizu; H. Kaneda; H. Horinouchi; K. Watanabe; T. Yoshida; K. Hasegawa; K. Onishi; K. Yoshimura; T. Sawa; A. Gemma

  Journal of Thoracic Oncology Elsevier BV 16 (10) S1133 - S1133 1556-0864 2021/10
• オンコマイン検査成功率改善に向けた検査内製化と検査工程の見直し

  白石 直樹; 田中 薫; 高濱 隆幸; 鈴木 慎一郎; 金村 宙昌; 磯本 晃佑; 林 秀敏; 米阪 仁雄; 中川 和彦

  肺癌 (NPO)日本肺癌学会 61 (6) 649 - 649 0386-9628 2021/10
• EORTC QLQ-INFO25による患者の情報取得と満足度調査の結果報告 2021年版患者向けガイドブック改訂

  高濱 隆幸; 清水 秀文; 堀之内 秀仁; 吉田 健史; 渡邊 清高; 金田 裕靖; 長谷川 一男; 大西 幸次; 吉村 健一; 澤 祥幸; 弦間 昭彦

  肺癌 (NPO)日本肺癌学会 61 (6) 586 - 586 0386-9628 2021/10
• 小細胞癌のICI(Treatment of SCLC) 進展型小細胞肺癌における腫瘍微小免疫環境の網羅的解析

  金村 宙昌; 林 秀敏; 大谷 知之; 冨田 秀太; 鈴木 慎一郎; 原谷 浩司; 谷崎 潤子; 津谷 あす香; 福田 泰; 金田 裕靖; 工藤 慶太; 高濱 隆幸; 今井 亮介; 千葉 康敬; 西尾 和人; 伊藤 彰彦; 中川 和彦

  肺癌 (NPO)日本肺癌学会 61 (6) 499 - 499 0386-9628 2021/10
• CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.

  Ryoji Kato; Hidetoshi Hayashi; Kazuko Sakai; Shinichiro Suzuki; Koji Haratani; Takayuki Takahama; Junko Tanizaki; Yoshikane Nonagase; Kaoru Tanaka; Takeshi Yoshida; Masayuki Takeda; Kimio Yonesaka; Hiroyasu Kaneda; Kazuto Nishio; Kazuhiko Nakagawa

  International journal of clinical oncology 26 (9) 1628 - 1639 1341-9625 2021/09 

  BACKGROUND: We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC). METHODS: The study included patients with EGFR activating mutation-positive advanced NSCLC who were positive for T790M in tumor tissue or plasma after previous treatment with an EGFR tyrosine kinase inhibitor, who received osimertinib at Kindai University Hospital between August 2014 and September 2017, and for whom plasma collected after progression on osimertinib was available. Clinical data were extracted from medical records. Patients with innate resistance to osimertinib were defined as those whose best response was progressive disease or stable disease for < 6 months, whereas patients with a complete or partial response or stable disease for > 6 months were considered as having acquired resistance. RESULTS: We performed CAPP-seq for 20 patients at progression on osimertinib. Distinct patterns of genomic alterations were apparent in patients with innate versus acquired resistance. Mutations in PIK3CA, KRAS, or BRAF and copy number gain for EGFR, ERBB2, or MET were more common in patients with innate resistance than in those with acquired resistance. In addition, one patient who underwent a repeat biopsy was found to harbor the C797S mutation of EGFR after disease progression during osimertinib rechallenge, with this mutation not having been detected at the time of initial progression on osimertinib. CONCLUSIONS: CAPP-seq analysis of ctDNA was able to identify potentially targetable genetic alterations in patients with osimertinib resistance.
• Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.

  Esuteru Hirokawa; Satomi Watanabe; Kazuko Sakai; Masayuki Takeda; Chihiro Sato; Takayuki Takahama; Kazuto Nishio; Kazuhiko Nakagawa

  Thoracic cancer 12 (16) 2283 - 2287 1759-7706 2021/08 

  Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been identified as an oncogenic driver in 0.05% to 0.14% of non-small cell lung cancer (NSCLC) patients. However, little is known of the efficacy of EGFR tyrosine kinase inhibitors (TKIs) for such patients. Here, we report the case of a 45-year-old Japanese woman with NSCLC positive for EGFR-KDD (duplication of exons 18-25) who developed carcinomatous meningitis and showed a marked response to the EGFR-TKIs erlotinib and osimertinib. As far as we are aware, this is the first report of EGFR-TKI efficacy for carcinomatous meningitis in a NSCLC patient harboring EGFR-KDD.
• MO16-3 Results of the first survey using EORTC QLQ INFO25 on information acquisition and satisfaction of lung cancer patients

  Hidefumi Shimizu; Takayuki Takahama; Hiroyasu Kaneda; Hidehito Horinouchi; Takeshi Yoshida; Kiyotaka Watanabe; Kazuo Hasegawa; Kouji Onishi; Kenichi Yoshimura; Toshiyuki Sawa; Akihiko Gemma

  Annals of Oncology Elsevier BV 32 S306 - S306 0923-7534 2021/07
• Implementation of clinical sequencing for molecular profiling in patients with advanced cancer.

  Tomoya Fukui; Kazuko Sakai; Jiichiro Sasaki; Mikiko Ishihara Kakegawa; Satoshi Igawa; Hisashi Mitsufuji; Masayuki Takeda; Takayuki Takahama; Kazuhiko Nakagawa; Kazuto Nishio; Katsuhiko Naoki

  Cancer biomarkers : section A of Disease markers 31 (2) 119 - 126 1574-0153 2021 

  BACKGROUND: The advancement of cancer genomics has allowed for multiplex gene assays using next-generation sequencing (NGS) to be practically implemented, however, a clinical practice system remains to be established. OBJECTIVE: We evaluated the feasibility of clinical sequencing using NGS-based multiplex gene assays between cooperating medical institutions in patients with advanced cancers. METHODS: In this observational study, DNA and RNA samples prepared from existing tumor tissues were subjected to comprehensive genomic profiling using targeted sequencing. RESULTS: From January 2017 to March 2019, 36 samples from 33 patients were assessed. Of all patients, 27 (82%) had lung cancer, with the median age of 50 years (range 38-83). Multiplex gene panel tests were successfully carried out on 35/36 (97%) samples. Potentially actionable gene alterations were identified in 10/30 (33%) samples (3 HER2, 2 KRAS, 2 ALK, 1 PIK3CA, 1 RET, and 1 CDKN2A). In the 6 samples examined for resistant mechanisms, ALK I1171N mutation and MET copy number gain were detected in 2 patients with ALK rearrangement-positive lung cancer. CONCLUSIONS: Clinical sequencing using NGS-based multiplex gene assays between collaborating domestic medical institutions was feasible, with a success rate of > 97%. Overall, clinical sequencing benefits therapeutic decision-making in patients with advanced cancer.
• Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).

  Kazuko Sakai; Takayuki Takahama; Mototsugu Shimokawa; Koichi Azuma; Masayuki Takeda; Terufumi Kato; Haruko Daga; Isamu Okamoto; Hiroaki Akamatsu; Shunsuke Teraoka; Akira Ono; Tatsuo Ohira; Toshihide Yokoyama; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Kazuto Nishio

  Molecular oncology Wiley 15 (1) 126 - 137 1574-7891 2021/01 

  The WJOG8815L phase II clinical study involves patients with non-small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third-generation EGFR-TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR-TKI-sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing-and T790M-EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation-positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression-free survival were observed between the sensitizing EGFR MF-high and sensitizing EGFR MF-low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
• Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.

  Masayuki Takeda; Takayuki Takahama; Kazuko Sakai; Shigeki Shimizu; Satomi Watanabe; Hisato Kawakami; Kaoru Tanaka; Chihiro Sato; Hidetoshi Hayashi; Yoshikane Nonagase; Kimio Yonesaka; Naoki Takegawa; Tatsuya Okuno; Takeshi Yoshida; Soichi Fumita; Shinichiro Suzuki; Koji Haratani; Kazumasa Saigoh; Akihiko Ito; Tetsuya Mitsudomi; Hisashi Handa; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto Nishio

  The oncologist 26 (4) e588-e596 - e596 1083-7159 2020/12 

  BACKGROUND: Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive genomic profiling assays that may inform treatment recommendations for patients with solid tumors. MATERIALS AND METHODS: We performed a prospective study to evaluate the feasibility of application of the FoundationOne CDx panel-which detects substitutions, insertions and deletions, and copy number alterations in 324 genes, select gene rearrangements, and genomic signatures including microsatellite instability and tumor mutation burden (TMB)-to patients with advanced or recurrent solid tumors before its approval in Japan. RESULTS: A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%. The median turnaround time was 41 days (range, 21-126 days). The most common known or likely pathogenic variants were TP53 mutations (n = 113), PIK3CA mutations (n = 33), APC mutations (n = 32), and KRAS mutations (n = 29). Among the 153 patients assessed for TMB, the median TMB was 4 mutations/Mb, and tumors with a high TMB (≥10 mutations/Mb) were more prevalent for lung cancer (11/32) than for other solid tumor types (9/121, Fisher's exact test p < .01). No clear trend toward increased efficacy for immune checkpoint inhibitor (ICI) monotherapy or ICI combination chemotherapy in patients with a high programmed cell death-ligand 1 tumor proportion score or a high TMB was apparent. Among the 174 patients found to harbor known or likely pathogenic actionable alterations, 24 individuals (14%) received matched targeted therapy. CONCLUSION: The FoundationOne CDx assay was performed with formalin-fixed, paraffin-embedded tumor specimens with a success rate of >95%. Such testing may inform the matching of patients with cancer with investigational or approved targeted drugs. IMPLICATIONS FOR PRACTICE: This prospective cohort study was initiated to investigate the feasibility and utility of clinical application of FoundationOne CDx. A total of 181 samples were processed for genomic testing between September 2018 and June 2019, with data being successfully obtained for 175 of these samples, yielding a success rate of 96.7%, and 24 individuals (14%) received matched targeted therapy.
• CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討

  加藤 了資; 林 秀敏; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 野長瀬 祥兼; 田中 薫; 吉田 健史; 武田 真幸; 米阪 仁雄; 中川 和彦; 坂井 和子; 西尾 和人; 金田 裕靖

  肺癌 (NPO)日本肺癌学会 60 (2) 148 - 148 0386-9628 2020/04
• Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer

  Kurosaki, T.; Kawakami, H.; Mitani, S.; Kawabata, R.; Takahama, T.; Nonagase, Y.; Fumita, S.; Ozaki, T.; Chiba, Y.; Tamura, T.; Nakagawa, K.

  In vivo (Athens, Greece) Anticancer Research USA Inc. 34 (4) 1921 - 1929 0258-851X 2020 [Refereed]
   

  Background/Aim: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) of which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), which reflects systemic inflammatory and nutritional status as well as disease control by chemotherapy immediately before nivolumab (DCBC). Patients and Methods: AGC patients with measurable lesions who were treated with nivolumab in the third- or later-line were included. DCBC was defined as a best overall response of complete response (CR), partial response, stable disease, or non-CR/non-progressive disease achieved by chemotherapy immediately before nivolumab. Results: Eighty patients were analyzed. Among the various clinical factors, multivariable analysis revealed that a GPS of 2 was significantly associated with a shorter overall survival and DCBC was significantly associated with a longer progression-free survival. Conclusion: We present the potential of GPS and DCBC as efficient biomarkers of nivolumab for AGC, that warrants further evaluation.
• Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.

  Masayuki Takeda; Kazuko Sakai; Hidetoshi Hayashi; Kaoru Tanaka; Koji Haratani; Takayuki Takahama; Ryoji Kato; Kimio Yonesaka; Kazuto Nishio; Kazuhiko Nakagawa

  Lung cancer (Amsterdam, Netherlands) 139 28 - 34 0169-5002 2020/01 [Refereed]
   

  OBJECTIVES: The T790M secondary mutation of epidermal growth factor receptor gene (EGFR) is the most common mechanism of acquired resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). We investigated the association between gene mutation profile in EGFR mutation-positive non-small cell lung cancer (NSCLC) before EGFR-TKI treatment and T790M status after EGFR-TKI treatment. MATERIALS AND METHODS: A total of 57 EGFR mutation-positive NSCLC patients who had undergone a repeat biopsy (tissue or liquid) after failure of treatment with a first- or second-generation EGFR-TKI and who had sufficient tumor tissue available from before treatment for genetic analysis was enrolled. The gene mutation profile of tumor tissue obtained before EGFR-TKI treatment was evaluated by next-generation sequencing with a comprehensive cancer gene panel (409 genes). The number of potentially damaging nonsynonymous mutations was predicted with PolyPhen-2 software. RESULTS: Progression-free survival during EGFR-TKI treatment did not differ significantly between patients who developed T790M-mediated resistance and those who developed T790M-independent resistance. The predicted number of damaging nonsynonymous mutations in pretreatment tumor tissue was significantly lower in patients who developed T790M-mediated resistance than in those with T790M-independent resistance (P =  0.049). CONCLUSIONS: Coexisting mutations in tumor tissue before EGFR-TKI treatment may contribute to the emergence of cell clones responsible for development of T790M-dependent or T790M-independent TKI resistance in patients with EGFR-mutated NSCLC. Multiplex genomic testing of pretreatment tumor tissue may thus provide a means of identifying patients likely to develop T790M-mediated TKI resistance and therefore inform treatment selection.
• Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.

  Takayuki Takahama; Koichi Azuma; Mototsugu Shimokawa; Masayuki Takeda; Hidenobu Ishii; Terufumi Kato; Haruhiro Saito; Haruko Daga; Yuko Tsuboguchi; Isamu Okamoto; Kohei Otsubo; Hiroaki Akamatsu; Shunsuke Teraoka; Toshiaki Takahashi; Akira Ono; Tatsuo Ohira; Toshihide Yokoyama; Kazuko Sakai; Nobuyuki Yamamoto; Kazuto Nishio; Kazuhiko Nakagawa

  Cancer Wiley 126 (9) 1940 - 1948 0008-543X 2020/01 [Refereed]
   

  BACKGROUND: Liquid biopsy allows the identification of patients whose tumors harbor specific mutations in a minimally invasive manner. No prospective data have been available for the efficacy of osimertinib in patients with non-small cell lung cancer (NSCLC) who develop resistance to first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and who test positive for the TKI resistance-conferring T790M mutation of EGFR by liquid biopsy. Therefore, a phase 2 study was conducted to assess the efficacy and safety of osimertinib in such patients. METHODS: Eligible patients had advanced or recurrent NSCLC with known TKI-sensitizing mutations of EGFR, had documented disease progression after treatment with at least 1 first- or second-generation EGFR TKI, and were positive for the T790M mutation in plasma according to the Cobas EGFR Mutation Test v2 (Roche Diagnostics) or droplet digital polymerase chain reaction analysis. Patients were treated with osimertinib (80 mg/d) until disease progression. The primary endpoint was the overall response rate (ORR) in patients positive for T790M in plasma by the Cobas assay. RESULTS: Between June 2016 and November 2017, 276 patients were screened for their T790M status with a liquid biopsy. Seventy-four patients were positive for T790M in plasma, and 53 of these individuals were enrolled in the study. The ORR for evaluable patients positive for T790M in plasma by the Cobas assay (n = 49) was 55.1% (95% confidence interval [CI], 40.2%-69.3%). The median progression-free survival for all evaluable patients (n = 52) was 8.3 months (95% CI, 6.9-12.6 months). CONCLUSIONS: The results demonstrate the utility of liquid biopsy for the detection of T790M with the Cobas EGFR Mutation Test v2. Plasma genotyping with this assay is informative for treatment selection in clinical practice when tumor sampling is not feasible.
• Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

  Kimio Yonesaka; Eiji Iwama; Hidetoshi Hayashi; Shinichiro Suzuki; Ryoji Kato; Satomi Watanabe; Takayuki Takahama; Junko Tanizaki; Kaoru Tanaka; Masayuki Takeda; Kazuko Sakai; Koichi Azuma; Yasutaka Chiba; Shinji Atagi; Kazuto Nishio; Isamu Okamoto; Kazuhiko Nakagawa

  Scientific reports 9 (1) 19501 - 19501 2019/12 [Refereed]
   

  Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard therapy for EGFR-mutant non-small cell lung cancer (NSCLC). Preclinically, HER3 ligand heregulin induces resistance to EGFR-TKIs, whereas the pan-human EGFR family inhibitor afatinib remains effective. Here, we examined whether soluble heregulin levels have clinical implications for EGFR-mutant NSCLC treated with EGFR-TKIs. Soluble heregulin was immunologically measured in plasma from EGFR-mutant NSCLC patients. Cutoff values were determined by 1-year PFS ROC curve. The relationship between soluble heregulin and PFS following EGFR-TKI therapy was analyzed by Cox proportional hazards model. Seventy-three patients were enrolled: 44 were treated with 1st-generation and 29 with 2nd-generation EGFR-TKIs. Soluble heregulin levels varied (range: 274-7,138 pg/mL, median: 739 pg/mL). Among patients treated with 1st-generation EGFR-TKIs, those with high heregulin (n = 20, >800 pg/mL) had a tendency for shorter PFS than those with low heregulin (n = 24, <800 pg/mL), with median PFS of 322 and 671 days, respectively. Cox proportional hazards model also indicated a trend toward resistance against 1st-generation EGFR-TKIs (HR: 1.825, 95% CI: 0.865-4.318) but not against 2nd-generation EGFR-TKIs. Soluble heregulin potentially correlates with resistance to EGFR-TKIs but not 2nd-generation EGFR-TKIs in patients with EGFR-mutant NSCLC.
• A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.

  Satomi Watanabe; Tomoyuki Otani; Tsutomu Iwasa; Takayuki Takahama; Masayuki Takeda; Kazuko Sakai; Kazuto Nishio; Akihiko Ito; Kazuhiko Nakagawa

  Clinical breast cancer 19 (5) e589-e592 - e592 1526-8209 2019/10 [Refereed]
  
• Clinical and immune profiling for cancer of unknown primary site.

  Koji Haratani; Hidetoshi Hayashi; Takayuki Takahama; Yasushi Nakamura; Shuta Tomida; Takeshi Yoshida; Yasutaka Chiba; Takahiro Sawada; Kazuko Sakai; Yoshihiko Fujita; Yosuke Togashi; Junko Tanizaki; Hisato Kawakami; Akihiko Ito; Kazuto Nishio; Kazuhiko Nakagawa

  Journal for immunotherapy of cancer 7 (1) 251 - 251 2019/09 [Refereed]
   

  BACKGROUND: Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP for immunotherapy. METHODS: A total of 164 patients with CUP (favorable subset, 34 patients; unfavorable subset, 130 patients) who were treated between January 2009 and March 2017 was identified from a review of medical records at Kindai University Hospital. They included 92 patients for whom pretreatment tumor tissue was available both for determination of programmed cell death-ligand 1 expression and tumor-infiltrating lymphocyte (TIL) density by immunohistochemistry (IHC) and for immune-related gene expression profiling (irGEP). The results of irGEP for CUP were compared with published data for ICI-treated solid cancers classified into progressive disease (PD) and non-PD subsets according to their best response to ICIs. RESULTS: The median overall survival of all CUP patients was 29.3 months (95% confidence interval [CI], 15.7-not reached) and 7.1 months (95% CI, 5.0-9.4) for favorable and unfavorable subsets, respectively. IHC and irGEP revealed that pretreatment immune activity-including expression of immune checkpoint molecules-for CUP was similar to that for ICI-responsive malignancies (antitumor immune cell signatures: CUP versus PD, P = 0.002-0.067; CUP versus non-PD, P = 0.591-0.999), although VEGFA expression was associated with suppression of antitumor immunity in CUP (P = 0.008, false discovery rate = 0.010). In addition, one case of CUP in the unfavorable subset that was associated with prominent PD-L1 expression on TILs and showed a durable response to nivolumab is presented. CONCLUSIONS: The survival outcome of CUP remains unsatisfactory. However, our clinical and immune profiling of CUP has revealed a potential to benefit from immunotherapy, with ICIs thus being a potential option for CUP treatment.
• A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.

  Kazuko Sakai; Masayuki Takeda; Shigeki Shimizu; Takayuki Takahama; Takeshi Yoshida; Satomi Watanabe; Tsutomu Iwasa; Kimio Yonesaka; Shinichiro Suzuki; Hidetoshi Hayashi; Hisato Kawakami; Yoshikane Nonagase; Kaoru Tanaka; Junji Tsurutani; Kazumasa Saigoh; Akihiko Ito; Tetsuya Mitsudomi; Kazuhiko Nakagawa; Kazuto Nishio

  Scientific reports 9 (1) 11340 - 11340 2019/08 [Refereed]
   

  Medical oncologists are challenged to personalize medicine with scientific evidence, drug approvals, and treatment guidelines based on sequencing of clinical samples using next generation sequencer (NGS). Knowledge-based curation systems have the potential to help address this challenge. We report here the results of examining the level of evidence regarding treatment approval and clinical trials between recommendations made by Watson for Genomics (WfG), QIAGEN Clinical Insight Interpret (QCII), and Oncomine knowledge-based reporter (OKR). The tumor samples obtained from the solid cancer patients between May to June 2018 at Kindai University Hospital. The formalin-fixed paraffin-embedded tumor samples (n = 31) were sequenced using Oncomine Comprehensive Assay v3. Variants including copy number alteration and gene fusions identified by the Ion reporter software were used commonly on three curation systems. Curation process of data were provided for 25 solid cancers using three curation systems independently. Concordance and distribution of curated evidence levels of variants were analyzed. As a result of sequencing analysis, nonsynonymous mutation (n = 58), gene fusion (n = 2) or copy number variants (n = 12) were detected in 25 cases, and subsequently subjected to knowledge-based curation systems (WfG, OKR, and QCII). The number of curated information in any systems was 51/72 variants. Concordance of evidence levels was 65.3% between WfG and OKR, 56.9% between WfG and QCII, and 66.7% between OKR and QCII. WfG provided great number of clinical trials for the variants. The annotation of resistance information was also observed. Larger differences were observed in clinical trial matching which could be due to differences in the filtering process among three curation systems. This study demonstrates knowledge-based curation systems (WfG, OKR, and QCII) could be helpful tool for solid cancer treatment decision making. Difference in non-concordant evidence levels was observed between three curation systems, especially in the information of clinical trials. This point will be improved by standardized filtering procedure and enriched database of clinical trials in Japan.
• New Era for Next-Generation Sequencing in Japan.

  Masayuki Takeda; Kazuko Sakai; Takayuki Takahama; Kazuya Fukuoka; Kazuhiko Nakagawa; Kazuto Nishio

  Cancers 11 (6) 2019/05 [Refereed]
   

  : Recent progress in understanding the molecular basis of cancer-including the discovery of cancer-associated genes such as oncogenes and tumor suppressor genes-has suggested that cancer can become a treatable disease. The identification of driver oncogenes such as EGFR, ALK, ROS1, BRAF and HER2 has already been successfully translated into clinical practice for individuals with solid tumor. Next-generation sequencing (NGS) technologies have led to the ability to test for multiple cancer-related genes at once with a small amount of cells and tissues. In Japan, several hospitals have started NGS-based mutational profiling screening in patients with solid tumor in order to guide patients to relevant clinical trials. The Ministry of Health, Labor, and Welfare of Japan has also approved several cancer gene panels for use in clinical practice. However, there is an urgent need to develop a medical curriculum of clinical variant interpretation and reporting. We review recent progress in the implementation of NGS in Japan.
• Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.

  Shinichiro Suzuki; Koji Haratani; Takayuki Takahama; Satomi Watanabe; Naoki Takegawa; Hidetoshi Hayashi; Masayuki Takeda; Kimio Yonesaka; Kazuhiko Nakagawa

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 14 (3) e50-e52 - e52 1556-0864 2019/03 [Refereed]
  
• Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer.

  Hiroto Ueda; Hisato Kawakami; Yoshikane Nonagase; Naoki Takegawa; Tatsuya Okuno; Takayuki Takahama; Masayuki Takeda; Yasutaka Chiba; Takao Tamura; Kazuhiko Nakagawa

  The oncologist 24 (2) 163-e76 - e76 1083-7159 2019/02 [Refereed]
   

  LESSONS LEARNED: The 5-fluorouracil, docetaxel, and nedaplatin (UDON) regimen was well tolerated and showed promising antitumor activity in terms of both objective response rate and survival for patients with advanced or recurrent esophageal squamous cell carcinoma in the first-line setting.UDON may be an optimal treatment option for patients with advanced esophageal cancer who are unfit for docetaxel, cisplatin, and 5-fluorouracil regimens.The high response rate as well as the rapid and marked tumor shrinkage associated with UDON suggest that further evaluation of this regimen in the neoadjuvant setting is warranted. BACKGROUND: A phase II study was performed to evaluate the efficacy and safety of 5-fluorouracil (5-FU), docetaxel, and nedaplatin (UDON) combination therapy for untreated recurrent or metastatic esophageal cancer. METHODS: Patients received intravenous nedaplatin (90 mg/m2) on day 1, docetaxel (35 mg/m2) on days 1 and 15, and 5-fluorouracil (800 mg/m2) on days 1-5 of a 4-week cycle. The primary endpoint was response rate, with secondary endpoints including overall survival (OS), progression-free survival (PFS), dysphagia score, and adverse events. RESULTS: Between March 2015 and July 2017, 23 patients were enrolled. Of 22 evaluable patients, 16 and 4 individuals experienced a partial response and stable disease, respectively, yielding a response rate of 72.7% (95% confidence interval [CI], 49.8%-89.3%) and disease control rate of 90.9% (95% CI, 70.8%-98.9%). Median OS and PFS were 11.2 months (95% CI, 9.1 months to not reached) and 6.0 months (95% CI, 2.5-10.6 months), respectively. Eleven (64.7%) of the 17 patients with a primary lesion showed amelioration of dysphagia after treatment. Frequent adverse events of grade 3 or 4 included neutropenia (87.0%) and leukopenia (39.1%). Febrile neutropenia was observed in two patients (8.7%). CONCLUSION: This phase II study demonstrated promising antitumor activity and good tolerability of UDON.
• 気管支肺胞洗浄液と血清における腫瘍マーカーであるサイトケラチンフラグメント値の比較(Comparison of Tumor Marker Cytokeratin Fragment Levels in Bronchoalveolar Lavage and Serum)

  Fujita Etsuo; Ohya Daichi; Kitamura Yousuke; Yamamura Risa; Ishikawa Kana; Sagimori Miki; Ohta Fuminori; Kiyoi Megumi; Kawabata Yoshitaka; Hashimoto Tadayuki; Aoki Tatsuya; Kayama Yuta; Mukai Yosuke; Nakamura Ryo; Yabuuchi Toshinobu; Furuta Katsuyuki; Hikimoto Shigetoshi; Takahata Masahiro; Sougawa Hiromichi; Kobayashi Katsunobu; Hoshiya Hironobu; Nakachi Kenichiro; Ikejima Miwa; Furukawa Kenichi; Kawahara Masaaki; Takahama Takayuki; Nishikawa Yusaku; Tohda Yuji; Shimada Kousuke; Yamamoto Katsuhiro

  日本臨床生理学会雑誌 日本臨床生理学会 48 (3) 127 - 133 0286-7052 2018/08 

  肺癌の診断に気管支肺胞洗浄液(BAL)のサイトケラチンフラグメント(CYFRA)を使用できるか検討するため、患者39名(男31名、女8名、平均年齢73.2±1.6歳)のBALにおけるCYFRA濃度を測定した。全員のBALのCYFRA値は49.4±21.8ng/mLで、そのうち悪性と診断された患者27名の値は38.0±12.9ng/mL、良性病変の患者12名の値は75.0±66.0ng/mLで、有意差は認めなかった。一方、血清中のCYFRA値は、全員、悪性、良性の患者でそれぞれ、4.5±0.8ng/mL、5.5±1.1ng/mL、2.3±0.6ng/mLであった。BALのCYFRAの平均値は悪性の症例よりも良性の症例で高く、血清CYFRA値では悪性の症例のほうが高い傾向がみられた。
• B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

  Kimio Yonesaka; Koji Haratani; Shiki Takamura; Hitomi Sakai; Ryoji Kato; Naoki Takegawa; Takayuki Takahama; Kaoru Tanaka; Hidetoshi Hayashi; Masayuki Takeda; Sigeki Kato; Osamu Maenishi; Kazuko Sakai; Yasutaka Chiba; Takafumi Okabe; Keita Kudo; Yoshikazu Hasegawa; Hiroyasu Kaneda; Michiko Yamato; Kenji Hirotani; Masaaki Miyazawa; Kazuto Nishio; Kazuhiko Nakagawa

  Clinical cancer research : an official journal of the American Association for Cancer Research American Association for Cancer Research Inc. 24 (11) 2653 - 2664 1557-3265 2018/06 [Refereed]
   

  Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non-small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed in various malignancies. To our knowledge, this study is the first to evaluate B7-H3 expression in NSCLCs treated with anti-PD-1 therapy and the therapeutic potential of a combination of anti-PD-1 therapy and B7-H3 targeting.Experimental Design: B7-H3 expression was evaluated immunohistochemically in patients with NSCLC (n = 82), and its relationship with responsiveness to anti-PD-1 therapy and CD8+ tumor-infiltrating lymphocytes (TILs) was analyzed. The antitumor efficacy of dual anti-B7-H3 and anti-programmed death ligand-1 (PD-L1) antibody therapy was evaluated using a syngeneic murine cancer model. T-cell numbers and functions were analyzed by flow cytometry.Results: B7-H3 expression was evident in 74% of NSCLCs and was correlated critically with nonresponsiveness to anti-PD-1 immunotherapy. A small number of CD8+ TILs was observed as a subpopulation with PD-L1 tumor proportion score less than 50%, whereas CD8+ TILs were still abundant in tumors not expressing B7-H3. Anti-B7-H3 blockade showed antitumor efficacy accompanied with an increased number of CD8+ TILs and recovery of effector function. CD8+ T-cell depletion negated antitumor efficacy induced by B7-H3 blockade, indicating that improved antitumor immunity is mediated by CD8+ T cells. Compared with a single blocking antibody, dual blockade of B7-H3 and PD-L1 enhanced the antitumor reaction.Conclusions: B7-H3 expressed on tumor cells potentially circumvents CD8+-T-cell-mediated immune surveillance. Anti-B7-H3 immunotherapy combined with anti-PD-1/PD-L1 antibody therapy is a promising approach for B7-H3-expressing NSCLCs. Clin Cancer Res; 24(11); 2653-64. ©2018 AACR.
• Potential research and clinical utility of liquid biopsy with CAPP seq

  Takahama, T.; Sakai, K.; Nakagawa, K.; Nishio, K.

  Annals of Oncology 29 2018
• Phase II study of osimertinib in patients with plasma EGFR T790M positive advanced lung cancer (WJOG8815L/LPS)

  Takahama, T.; Azuma, K.; Shimokawa, M.; Kato, T.; Daga, H.; Okamoto, I.; Akamatsu, H.; Takahashi, T.; Ohira, T.; Yokoyama, T.; Hirano, K.; Shiraishi, Y.; Himeji, D.; Yamamoto, N.; Nishio, K.; Nakagawa, K.

  Annals of Oncology 29 2018 [Refereed]
  
• 血清との比較による、気管支肺胞洗浄液(BAL)中の腫瘍マーカーである扁平上皮癌(SCC)の測定(Tumor Marker Measurement of Squamous Cell Carcinoma (SCC) Antigen in Bronchial Alveolar Lavage (BAL) Compared to Serum One)

  Fujita Etsuo; Shojima Kensaku; Nishimura Hideko; Hattori Maiko; Takahata Masahiro; Sougawa Hiromichi; Kobayashi Katsunobu; Hoshiaya Hironobu; Ohta Fuminori; Kiyoi Megumi; Nakai Takeo; Tsunoi Kazuyuki; Sakanaka Keiichiro; Tanaka Akio; Deguchi Yoko; Horiuchi Yuko; Iwahashi Naoyuki; Furukawa Kenichi; Hirabayashi Yasuo; Inagaki Takashi; Kawahara Masaaki; Takahama Takayuki; Nakanishi Yuya; Nishikawa Yusaku; Tohda Yuji; Shimada Kousuke; Yamamoto Katsuhiro

  日本臨床生理学会雑誌 日本臨床生理学会 47 (2) 105 - 111 0286-7052 2017/05 

  BAL中のSCCを測定して肺癌の診断を行い、血清SCC測定結果と比較した。肺癌の疑いのある患者68名(男48名、女20名、平均71.4名)に、PETとGaシンチグラフィーを行い、経気管支鏡肺生検、経気管支鏡生検またはBALを含む組織検査または細胞診を行った。肺癌患者ではBAL中のSCC抗原マーカー(435.5±61.1ng/mL)は、良性病変(354.2±86.9ng/mL)よりもわずかに高値を示した。血清のSCC抗原マーカー(3.3±0.9ng/mL)も良性病変(1.3±0.1ng/mL)よりもわずかに高値を示した。以上より、この測定値を他の放射線画像診断と併用すると、肺癌の診断の信頼性が高くなると考えられた。
• Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.

  Yoshikane Nonagase; Kimio Yonesaka; Hisato Kawakami; Satomi Watanabe; Koji Haratani; Takayuki Takahama; Naoki Takegawa; Hiroto Ueda; Junko Tanizaki; Hidetoshi Hayashi; Takeshi Yoshida; Masayuki Takeda; Yasutaka Chiba; Takao Tamura; Kazuhiko Nakagawa; Junji Tsurutani

  Oncotarget IMPACT JOURNALS LLC 7 (51) 84860 - 84871 1949-2553 2016/12 [Refereed]
   

  BACKGROUND: Overexpression of heregulin, a HER3 ligand, is one mechanism that confers resistance to the anti-HER2 agents trastuzumab and lapatinib. We investigated the impact of heregulin expression on the efficacy of HER2-targeted therapeutic agents, including trastuzumab, trastuzumab emtansine (T-DM1) and lapatinib, in vitro and in vivo and evaluated the heregulin messenger RNA (mRNA) levels in specimens from patients with HER2-positive breast or gastric cancer. RESULTS: Cell proliferation and apoptosis assays demonstrated that heregulin conferred robust resistance to lapatinib and trastuzumab via HER3-Akt pathway activation followed by survivin overexpression; however, heregulin conferred minimal or no resistance to T-DM1 and paclitaxel. The heregulin mRNA level of one of 10 patients was up-regulated after the acquisition of resistance to trastuzumab-based therapy. MATERIALS AND METHODS: SK-BR-3, NCI-N87, BT-474, MDA-MB-453, HCC1954, SNU-216 and 4-1ST cells were pharmacologically treated with recombinant heregulin or transfected with the heregulin gene. We also assessed the expression of heregulin mRNA in HER2-positive breast or gastric cancer samples before and after trastuzumab-based therapy using a RT-PCR-based method. CONCLUSIONS: mRNA up-regulation of heregulin was observed in clinical breast cancer specimens during trastuzumab-based treatment, but heregulin overexpression had a limited effect on the sensitivity to T-DM1 in vitro and in vivo.
• Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).

  Takayuki Takahama; Kazuko Sakai; Masayuki Takeda; Koichi Azuma; Toyoaki Hida; Masataka Hirabayashi; Tetsuya Oguri; Hiroshi Tanaka; Noriyuki Ebi; Toshiyuki Sawa; Akihiro Bessho; Motoko Tachihara; Hiroaki Akamatsu; Shuji Bandoh; Daisuke Himeji; Tatsuo Ohira; Mototsugu Shimokawa; Yoichi Nakanishi; Kazuhiko Nakagawa; Kazuto Nishio

  Oncotarget IMPACT JOURNALS LLC 7 (36) 58492 - 58499 1949-2553 2016/09 [Refereed]
   

  INTRODUCTION: Next-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been developed to overcome resistance to earlier generations of such drugs mediated by a secondary T790M mutation of EGFR, but the performance of a second tumor biopsy to assess T790M mutation status can be problematic. METHODS: We developed and evaluated liquid biopsy assays for detection of TKI-sensitizing and T790M mutations of EGFR by droplet digital PCR (ddPCR) in EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI resistance. RESULTS: A total of 260 patients was enrolled between November 2014 and March 2015 at 29 centers for this West Japan Oncology Group (WJOG 8014LTR) study. Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites fluid from 41 patients were collected after the development of EGFR-TKI resistance. All plasma samples were genotyped successfully and the results were reported to physicians within 14 days. TKI-sensitizing and T790M mutations were detected in plasma of 120 (46.2%) and 75 (28.8%) patients, respectively. T790M was detected in 56.7% of patients with plasma positive for TKI-sensitizing mutations. For the 41 patients with paired samples obtained after acquisition of EGFR-TKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0% for TKI-sensitizing mutations and 65.9% for T790M. CONCLUSIONS: Noninvasive genotyping by ddPCR with cell-free DNA extracted from plasma is a promising approach to the detection of gene mutations during targeted treatment.
• Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.

  Satomi Watanabe; Masayuki Takeda; Takayuki Takahama; Tsutomu Iwasa; Junji Tsurutani; Junko Tanizaki; Toshio Shimizu; Kazuko Sakai; Yoshitaka Wada; Noritaka Isogai; Kazuto Nishio; Kazuhiko Nakagawa

  Investigational new drugs SPRINGER 34 (3) 394 - 6 0167-6997 2016/06 [Refereed]
   

  Extramammary Paget's disease is a malignant intraepithelial carcinoma, which constitutes less than 1 % of all vulvar malignancies. Surgical resection is the first treatment of choice and standard chemotherapy has not been established for advanced or recurrent disease. Experimental and clinical studies have identified human epidermal growth receptor 2 as a potential therapeutic target. A 63-year-old male was referred for recurrent extramammary Paget's disease after surgery. Human epidermal growth receptor 2 was shown to be overexpressed and amplified by immunohistochemical analysis and fluorescence in situ hybridization analysis, respectively. After two cycles of trastuzumab monotherapy, all lymph node metastases decreased in size. However, he experienced recurrence in the lymph nodes during the seven courses of trastuzumab. As a subsequent treatment, trastuzumab was administered in combination with docetaxel and pertuzumab; clinical response was sustained for 12 months without significant adverse events.
• Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer

  M. Takeda; K. Sakai; M. Terashima; H. Kaneda; H. Hayashi; K. Tanaka; K. Okamoto; T. Takahama; T. Yoshida; T. Iwasa; T. Shimizu; Y. Nonagase; K. Kudo; S. Tomida; T. Mitsudomi; K. Saigo; A. Ito; K. Nakagawa; K. Nishio

  ANNALS OF ONCOLOGY OXFORD UNIV PRESS 26 (12) 2477 - 2482 0923-7534 2015/12 

  The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual patients. Multiplex genomic testing can assist physicians in matching patients with approved or experimental targeted treatments. Background: The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate therapies for individual patients. We have now applied such testing to detect actionable mutations that may inform treatment recommendations in lung cancer. Patients and methods: We prospectively applied amplicon sequencing panels that cover both mutational hotspots in 22 genes related to lung and colon tumorigenesis as well as 72 major variants of ALK, RET, ROS1, and NTRK1 fusion transcripts. We then determined the proportion of patients who received genotype-directed therapy and their overall survival (OS). Results: Tumor specimens from 110 patients with lung cancer recruited between July 2013 and March 2015 were analyzed. The most common genetic alterations were TP53 mutations in 42 patients, followed by EGFR mutations in 25, STK11 mutations in 12, and KRAS mutations in 10. Potentially actionable mutations were identified in 44 patients including 50% of those with adenocarcinoma and 14% of those with squamous cell carcinoma. The OS of patients with advanced or recurrent cancer who had an actionable mutation and received targeted therapy (median OS not achieved) was significantly longer than that of those with no mutation (18.1 months, P = 0.041) or of those with a mutation not so treated (6.1 months, P = 0.0027). Conclusions: Multiplex genomic testing was performed on formalin-fixed, paraffin-embedded tumor specimens with a success rate of >= 95%. Such testing can assist physicians in matching patients with approved or experimental targeted treatments. Clinical trial registration: The University Medical Hospital Information Network (UMIN) Clinical Trials Registry under the identifier UMIN000014782.
• The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.

  Kimio Yonesaka; Keita Kudo; Satomi Nishida; Takayuki Takahama; Tsutomu Iwasa; Takeshi Yoshida; Kaoru Tanaka; Masayuki Takeda; Hiroyasu Kaneda; Isamu Okamoto; Kazuto Nishio; Kazuhiko Nakagawa

  Oncotarget IMPACT JOURNALS LLC 6 (32) 33602 - 11 1949-2553 2015/10 [Refereed]
   

  Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to first generation EGFF-TKIs such as erlotinib. Heregulin activates HER3 in an autocrine fashion and causes erlotinib resistance in NSCLC. Here we examine whether afatinib is effective against heregulin-overexpressing NSCLCs harboring EGFR activating mutations. Afatinib but not erlotinib decreased EGFR mutant NSCLC PC9HRG cell proliferation in vitro and in mouse xenografts. Afatinib inhibited phosphorylation of the cell signaling pathway proteins HER3, EGFR, HER2, and HER4, likely by prevention of trans-phosphorylation as HER3 kinase activity is inadequate for auto-phosphorylation. Afatinib, unlike erlotinib, inhibited AKT activation, resulting in elevated apoptosis in PC9HRG cells. Clinically, a subpopulation of 33 patients with EGFR mutations and NSCLC who had received first generation EGFR-TKIs exhibited elevated plasma heregulin levels compared to healthy volunteers; one of these achieved a response with afatinib therapy despite having previously developed erlotinib resistance. Afatinib can overcome heregulin-mediated resistance to erlotinib in EGFR mutant NSCLC. Further studies are necessary to determine whether heregulin can predict afatinib efficacy after development offirst generation EGFR-TKI resistance.
• A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer.

  Takayuki Takahama; Masayuki Takeda; Shinichi Nishina; Kazuhiko Nakagawa

  BMC research notes BioMed Central Ltd. 8 (1) 100 - 100 1756-0500 2015/03 [Refereed]
   

  BACKGROUND: Trastuzumab + chemotherapy is considered the standard therapy for advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer with mild manageable toxicity, on the basis of the results of a pivotal phase-III trial. Cerebrovascular events are not recognized as expected adverse effects of such therapy. CASE PRESENTATION: We report the case of a 67-year-old, current-smoking male with stage-IV HER2-positive gastric cancer who suffered right middle cerebral artery (MCA) embolism after trastuzumab + chemotherapy. He received trastuzumab and cisplatin on Day 1, followed by a continuous 5-fluorouracil infusion for 5 days as a first-line treatment. Four days after chemotherapy initiation, he presented with left hemiplegia, and brain magnetic resonance imaging and magnetic resonance angiography revealed a right MCA occlusion. No further chemotherapy was administered because of worsening performance status. CONCLUSION: The present case, possibly the first such reported case, suggests the risk of development of embolism after trastuzumab + chemotherapy in HER2-positive advanced gastric cancer, although other factors should be considered.
• Anaplastic lymphoma kinase gene analysis as a useful tool for identifying primary unknown metastatic lung adenocarcinoma.

  Naoki Watanabe; Tomoya Ishii; Takayuki Takahama; Akira Tadokoro; Nobuhiro Kanaji; Hiroaki Dobashi; Shuji Bandoh

  Internal medicine (Tokyo, Japan) JAPAN SOC INTERNAL MEDICINE 53 (23) 2711 - 5 0918-2918 2014 [Refereed]
   

  A 55-year-old woman was admitted for an evaluation of a mediastinal mass, bilateral cervical lymphadenopathy and a left breast tumor. Although pathology revealed a diagnosis of breast cancer, the cervical lymph nodes differed from the breast lesion. An anaplastic lymphoma kinase (ALK) gene analysis revealed ALK rearrangement in the cervical lymph nodes only, which were therefore diagnosed as reflective of metastasis of lung adenocarcinoma. The mediastinal tumor was also diagnosed as an ALK-positive lung adenocarcinoma based on its therapeutic response. ALK gene analyses can be used to identify primary lesions in patients with cancers of unknown primary sites.
• Membranous glomerulonephritis associated with mycobacterium shimoidei pulmonary infection

  Nobuhiro Kanaji; Yoshio Kushida; Shuji Bandoh; Tomoya Ishii; Reiji Haba; Akira Tadokoro; Naoki Watanabe; Takayuki Takahama; Nobuyuki Kita; Hiroaki Dobashi; Takuya Matsunaga

  American Journal of Case Reports 14 543 - 547 1941-5923 2013/12 [Refereed]
   

  Objective: Background:Rare disease Membranous glomerulonephritis can occur secondarily from infectious diseases. There are no reports describing membranous glomerulonephritis caused by non-tuberculous mycobacterium infection. However, several cases with membranous glomerulonephritis due to Mycobacterium tuberculosis have been reported. Mycobacterium shimoidei is an uncommon pathogen, and less than 20 cases with this species have been reported. A therapeutic regimen for this infection has not been established yet. Case Report: An 83-year-old Japanese man presented with productive cough for 6 months. Computed tomography scan showed multiple cavities in the bilateral pulmonary felds. Acid-fast bacilli were evident in his sputum by Ziehl-Neelsen staining (Gafky 3). PCR amplifcations for Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium intracellulare were all negative. Finally, Mycobacterium shimoidei was identifed by rpoB sequencing and 16S rRNA sequencing. Urine examination showed a sub-nephrotic range of proteinuria and histology of the kidney showed membranous glomerulonephritis. Antimycobacterial treatment with clarithromycin, rifampicin, and ethambutol dramatically improved not only the pulmonary disease, but also the proteinuria. Conclusions: To the best of our knowledge, the presented case is the frst report showing non-tuberculous mycobacteriuminduced secondary membranous glomerulonephritis. A combination with clarithromycin, ethambutol, and rifampicin might be efective for treatment of Mycobacterium shimoidei infection. © Am J Case Rep.
• Membranous glomerulonephritis associated with Mycobacterium shimoidei pulmonary infection.

  Nobuhiro Kanaji; Yoshio Kushida; Shuji Bandoh; Tomoya Ishii; Reiji Haba; Akira Tadokoro; Naoki Watanabe; Takayuki Takahama; Nobuyuki Kita; Hiroaki Dobashi; Takuya Matsunaga

  The American journal of case reports 14 543 - 7 1941-5923 2013 [Refereed]
   

  PATIENT: Male, 83 FINAL DIAGNOSIS: Membranous glomerulonephritis Symptoms: Producting cough Medication: - Clinical Procedure: - Specialty: Nephrology. OBJECTIVE: Rare disease. BACKGROUND: Membranous glomerulonephritis can occur secondarily from infectious diseases. There are no reports describing membranous glomerulonephritis caused by non-tuberculous mycobacterium infection. However, several cases with membranous glomerulonephritis due to Mycobacterium tuberculosis have been reported. Mycobacterium shimoidei is an uncommon pathogen, and less than 20 cases with this species have been reported. A therapeutic regimen for this infection has not been established yet. CASE REPORT: An 83-year-old Japanese man presented with productive cough for 6 months. Computed tomography scan showed multiple cavities in the bilateral pulmonary fields. Acid-fast bacilli were evident in his sputum by Ziehl-Neelsen staining (Gaffky 3). PCR amplifications for Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium intracellulare were all negative. Finally, Mycobacterium shimoidei was identified by rpoB sequencing and 16S rRNA sequencing. Urine examination showed a sub-nephrotic range of proteinuria and histology of the kidney showed membranous glomerulonephritis. Antimycobacterial treatment with clarithromycin, rifampicin, and ethambutol dramatically improved not only the pulmonary disease, but also the proteinuria. CONCLUSIONS: To the best of our knowledge, the presented case is the first report showing non-tuberculous mycobacterium-induced secondary membranous glomerulonephritis. A combination with clarithromycin, ethambutol, and rifampicin might be effective for treatment of Mycobacterium shimoidei infection.
• Paraneoplastic focal segmental glomerulosclerosis in a patient with lung adenocarcinoma.

  Akira Tadokoro; Tomoya Ishii; Takayuki Takahama; Naoki Watanabe; Koshiro Takano; Nobuhiro Kanaji; Osamu Imataki; Hiroaki Dobashi; Shuji Bandoh; Takuya Matsunaga

  Internal medicine (Tokyo, Japan) JAPAN SOC INTERNAL MEDICINE 52 (17) 1953 - 6 0918-2918 2013 [Refereed]
   

  Focal segmental glomerulosclerosis (FSGS) is extremely rare among paraneoplastic nephrotic syndromes. We herein report a case of lung adenocarcinoma with nephrotic syndrome caused by paraneoplastic FSGS. A 68-year-old man visited our hospital for an evaluation of a right hilar mass on chest radiography and supraclavicular lymphadenopathy. Because an aspiration biopsy of the supraclavicular lymph node revealed adenocarcinoma, the patient was diagnosed with lung adenocarcinoma. He also had nephrotic syndrome, and the pathological findings of the renal biopsy demonstrated FSGS. Standard-dose carboplatin-containing chemotherapy led to a partial response for lung cancer and improved the patient's nephrotic syndrome without causing any adverse renal effects.
• Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy

  Nobuhiro Kanaji; Shuji Bandoh; Tomoya Ishii; Akira Tadokoro; Naoki Watanabe; Takayuki Takahama; Reiji Haba; Osamu Imataki; Hiroaki Dobashi; Takuya Matsunaga

  LUNG CANCER ELSEVIER IRELAND LTD 77 (2) 293 - 298 0169-5002 2012/08 [Refereed]
   

  The presence of fusion genes between the anaplastic lymphoma kinase (ALK) and echinoderm microtubule-associated protein-like 4 (EML4) genes is useful for determining appropriate molecular-targeted therapies in patients with non-small cell lung cancer (NSCLC). The diagnosis of NSCLC is often judged from transbronchial cytological specimens. The efficacy of RT-PCR for detection of EML4-ALK fusion genes in transbronchial cytological specimens has not been studied. Here, we evaluated the detection rate of EML4-ALK fusion genes in transbronchial cytological specimens positive for NSCLC by immediate cytology during bronchoscopic examination. Various numbers of H2228 cells carrying EML4-ALK variant 3 were combined with 1 x 10(6) wild-type WBCs. The RNA was extracted and the sensitivity of detection of the EML4-ALK fusion gene was determined using a nested RT-PCR. A total of 161 cell samples, from cases without available tissue samples, obtained by bronchoscopic examinations utilized for immediate cytology in patients with NSCLC were subsequently analyzed for EML4-ALK fusion genes using a nested multiplex RT-PCR. EML4-ALK variant 3 was detected in a small number of H2228 cells (10 cells), even in the presence of 1 x 106 WBCs (sensitivity: 0.001%). In the patient cytological samples, EML4-ALK fusion genes were detected in five of 161 NSCLCs (3.1%) and four of 88 adenocarcinomas (4.5%). Sequencing confirmed that these samples included three variant 1 genes, one variant 2 gene and one variant 3 gene. Using the same cytological samples, EGFR mutations were detected in 39 of 161 NSCLCs (24.2%) and 36 of 88 adenocarcinomas (40.9%). There was no case in which both EML4-ALK fusion and EGFR mutation were simultaneously detected. Rapid diagnosis during bronchoscopy utilizing immediate cytology contributed to the selection of the best samples for genetic analysis. EML4-ALK fusion genes as well as EGFR mutations were successfully detected in a small number of cancer cells from transbronchial cytological specimens using a nested multiplex RT-PCR. Our present strategy can be integrated into the clinical process without additional invasive examination of patients. In the era of molecular-targeted treatments for NSCLC, the combination of rapid diagnosis during bronchoscopic examination and stocking samples as cDNA could further correspond to genetic analyses of accumulating driver genes in NSCLC. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

MISC

• Providing Anti-Lung Cancer Drug Therapy Based on Genetic Information by Comprehensive Genomic Profiling

  米阪仁雄; 稲垣千昌; 稲垣千昌; 高濱隆幸; 高濱隆幸; 白石直樹; 磯本晃佑; 金村宙昌; 鈴木慎一郎; 谷崎潤子; 田中薫; 林秀敏; 中川和彦  日本癌学会学術総会抄録集(Web)  82nd-  2023
• 腫瘍微小環境における免疫細胞の局在と免疫チェックポイント阻害薬の効果との関連

  磯本晃佑; 原谷浩司; 田中薫; 谷崎潤子; 高濱隆幸; 金村宙昌; 鈴木慎一郎; 林秀敏  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 原発不明癌に対するニボルマブ治療中に肺サルコイド様肉芽腫変化をきたした一例

  川中雄介; 田中薫; 須田健一; 高濱隆幸; 林秀敏  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 超音波気管支鏡下針生検後に発症した細菌性心膜炎の一例

  村田修一; 谷崎潤子; 黒崎隆; 鈴木慎一郎; 高濱隆幸; 田中薫; 林秀敏  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 肺癌に対する遺伝子パネル検査の実際と出口戦略の検討

  高濱隆幸; 高濱隆幸; 米阪仁雄; 米阪仁雄; 谷崎潤子; 田中薫; 鈴木慎一郎; 金村宙昌; 磯本晃佑; 白石直樹; 坂井和子; 福岡和也; 福岡和也; 福岡和也; 西尾和人; 中川和彦; 中川和彦; 林秀敏  日本肺癌学会学術集会号  64th (CD-ROM)-  2023
• 進展型小細胞肺癌における免疫チェックポイント阻害薬の効果と腫瘍微小免疫環境の関連

  金村 宙昌; 林 秀敏; 原谷 浩司; 中川 和彦; 冨田 秀太; 谷崎 潤子; 鈴木 慎一郎; 川中 雄介; 津谷 あす香; 福田 泰; 金田 裕靖; 工藤 慶太; 高濱 隆幸; 今井 亮介; 千葉 康敬; 大谷 知之; 伊藤 彰彦; 坂井 和子; 西尾 和人  肺癌  62-  (5)  442  -442  2022/10
• 進行・再発非小細胞肺癌のバイオマーカー検査と標的治療に関する実態調査プロジェクト:WJOG15421L(REVEAL)

  阪本智宏; 松原太一; 高濱隆幸; 横山俊秀; 中村敦; 時任高章; 岡本龍郎; 赤松弘朗; 沖昌英; 佐藤悠城; 飛野和則; 西村邦裕; 平岡学; 釼持広知; 藤本淳也; 下川元継; 山本信之; 中川和彦  日本肺癌学会学術集会号  63rd (CD-ROM)-  2022
• 免疫療法における腫瘍縮小手術の役割-局所進行口腔粘膜悪性黒色腫の治療経験-

  木村隆浩; 高濱隆幸; 足立詩織; 若狭朋子; 明石雄策; 田村孝雄; 家根旦有; 桝井貴史; 上村裕和; 山中敏彰; 北原糺  日本頭頸部外科学会総会ならびに学術講演会プログラム・予稿集  31st-  2022
• 小細胞癌のICI(Treatment of SCLC) 進展型小細胞肺癌における腫瘍微小免疫環境の網羅的解析

  金村 宙昌; 林 秀敏; 大谷 知之; 冨田 秀太; 鈴木 慎一郎; 原谷 浩司; 谷崎 潤子; 津谷 あす香; 福田 泰; 金田 裕靖; 工藤 慶太; 高濱 隆幸; 今井 亮介; 千葉 康敬; 西尾 和人; 伊藤 彰彦; 中川 和彦  肺癌  61-  (6)  499  -499  2021/10
• EORTC QLQ-INFO25による患者の情報取得と満足度調査の結果報告 2021年版患者向けガイドブック改訂

  高濱 隆幸; 清水 秀文; 堀之内 秀仁; 吉田 健史; 渡邊 清高; 金田 裕靖; 長谷川 一男; 大西 幸次; 吉村 健一; 澤 祥幸; 弦間 昭彦  肺癌  61-  (6)  586  -586  2021/10
• オンコマイン検査成功率改善に向けた検査内製化と検査工程の見直し

  白石 直樹; 田中 薫; 高濱 隆幸; 鈴木 慎一郎; 金村 宙昌; 磯本 晃佑; 林 秀敏; 米阪 仁雄; 中川 和彦  肺癌  61-  (6)  649  -649  2021/10
• EGFR遺伝子変異陽性肺癌患者における、血漿検体による遺伝子変異検索方法と薬剤の有効性の検討

  高濱 隆幸  奈良県医師会医学会年報  34-  (1)  86  -90  2021/08
• 非小細胞肺癌に対するオンコマインDxTTを用いたドライバー遺伝子検査に関する多施設共同後ろ向き研究 WJOG13019L

  中村 敦; 坂田 晋也; 大坪 孝平; 伊藤 健太郎; 寺岡 俊輔; 松本 直久; 白石 祥理; 原谷 浩司; 田宮 基裕; 池田 慧; 益田 武; 時任 高章; 立原 素子; 高濱 隆幸; 吉田 寿子; 山本 信之; 中川 和彦  日本呼吸器学会誌  10-  (増刊)  144  -144  2021/04
• EORTC QLQ-INFO25を用いた肺癌患者の情報取得と満足度について初のアンケート調査結果

  金田 裕靖; 清水 秀文; 高濱 隆幸; 堀之内 秀仁; 吉田 健史; 渡邊 清高; 長谷川 一男; 大西 幸次; 吉村 健一; 澤 祥幸; 弦間 昭彦; 肺がん患者の会ワンステップ  日本呼吸器学会誌  10-  (増刊)  157  -157  2021/04
• 非小細胞肺癌に対するオンコマインDxTTを用いたドライバー遺伝子検査に関する多施設共同後ろ向き研究 WJOG13019L

  中村 敦; 坂田 晋也; 大坪 孝平; 伊藤 健太郎; 寺岡 俊輔; 松本 直久; 白石 祥理; 原谷 浩司; 田宮 基裕; 池田 慧; 益田 武; 時任 高章; 立原 素子; 高濱 隆幸; 吉田 寿子; 山本 信之; 中川 和彦  日本呼吸器学会誌  10-  (増刊)  144  -144  2021/04
• Results of the first survey using EORTC QLQ INFO25 on information acquisition and satisfaction of lung cancer patients

  清水秀文; 高濱隆幸; 金田裕靖; 堀之内秀仁; 吉田健史; 渡邊清高; 長谷川一男; 大西幸次; 吉村健一; 澤祥幸; 弦間昭彦  日本臨床腫瘍学会学術集会(CD-ROM)  10-  (増刊)  157  -157  2021/04
• Multi-disciplinary collaboration on gene panel testing and review of factors in cases of unsuitable for gene profiling

  高濱隆幸; 市村紀子; 岡部崇記; 明石雄策; 田村孝雄; 下吉都; 亀田啓介; 若狭朋子; 太田善夫; 山田秀和; 湯川真生  日本臨床腫瘍学会学術集会(CD-ROM)  18th-  2021
• Analysis of patients who were resistant to durvalumab after chemoradiotherapy in stag3 non-small-cell lung cancer

  岡部嵩記; 明石雄策; 高濱隆幸; 福田浩平; 井上恵理; 李在俊; 岡嶋馨; 若狭朋子; 太田善夫; 田村孝雄  日本臨床腫瘍学会学術集会(CD-ROM)  18th-  2021
• 当院におけるオンコマインDx Target TestマルチCDxシステムの使用経験と,ドライバー遺伝子陽性症例に関して

  明石雄策; 岡部崇記; 高濱隆幸; 若狭朋子; 太田善夫; 田村孝雄  日本臨床腫瘍学会学術集会(CD-ROM)  18th-  2021
• A multicenter retrospective study of Oncomine Dx Target Test Multi-CDx system for genetic profiling of NSCLC: WJOG13019L (DETECT-LC)

  中村敦; 坂田晋也; 大坪孝平; 伊藤健太郎; 寺岡俊輔; 松本直久; 白石祥理; 原谷浩司; 田宮基裕; 池田慧; 益田武; 時任高章; 立原素子; 高濱隆幸; 吉田寿子; 山本信之; 中川和彦  日本呼吸器学会誌(Web)  10-  2021
• Results of the first survey using EORTC QLQ-INFO25 on information acquisition and satisfaction of lung cancer patients

  金田裕靖; 清水秀文; 高濱隆幸; 堀之内秀仁; 吉田健史; 渡邊清高; 長谷川一男; 大西幸次; 吉村健一; 澤祥幸; 弦間昭彦  日本呼吸器学会誌(Web)  10-  2021
• 悪性腫瘍に対する気道インターベンションの検討

  高畠 弘幸; 楠本 英則; 塩野 裕之; 高濱 隆幸; 岡部 崇記; 明石 雄策; 井上 惠理; 福田 浩平  肺癌  60-  (6)  609  -609  2020/10
• Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)

  加藤晃史; 坂井和子; 高濱隆幸; 下川元継; 東公一; 武田真幸; 岡本勇; 駄賀晴子; 寺岡俊輔; 高橋利明; 大平達夫; 横山俊秀; 山本信之; 中川和彦; 西尾和人  日本臨床腫瘍学会学術集会(CD-ROM)  60-  (6)  630  -630  2020/10
• 悪性腫瘍に対する気道インターベンションの検討

  高畠 弘幸; 楠本 英則; 塩野 裕之; 高濱 隆幸; 岡部 崇記; 明石 雄策; 井上 惠理; 福田 浩平  肺癌  60-  (6)  609  -609  2020/10
• EGFR T790M変異陽性肺癌患者におけるオシメルチニブ治療とctDNAモニタリング(WJOG8815L)

  岩間 映二; 坂井 和子; 高濱 隆幸; 下川 元継; 東 公一; 武田 真幸; 加藤 晃史; 駄賀 晴子; 寺岡 俊輔; 高橋 利明; 大平 達夫; 横山 俊秀; 山本 信之; 中川 和彦; 西尾 和人  肺癌  60-  (6)  630  -630  2020/10
• 呼吸器疾患の克服に向けて 10年後の肺がん治療を考える〜若手医師が作る次世代の臨床研究〜 医師主導治験の計画と実施の実際

  高濱 隆幸  日本呼吸器学会誌  9-  (増刊)  34  -34  2020/08
• CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討

  加藤 了資; 林 秀敏; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 野長瀬 祥兼; 田中 薫; 吉田 健史; 武田 真幸; 米阪 仁雄; 中川 和彦; 坂井 和子; 西尾 和人; 金田 裕靖  肺癌  60-  (2)  148  -148  2020/04
• 非小細胞肺癌患者における免疫チェックポイント阻害薬による消化管irAEにおけるヒト・腸内細菌叢の病態と炎症性腸疾患の類似性に関する検討

  西尾 和人; 坂井 和子; 櫻井 俊治; 上嶋 一臣; 永井 知行; 林 秀敏; 川上 尚人; 高濱 隆幸; 武田 真幸; 中川 和彦  肺癌  60-  (2)  165  -165  2020/04
• 非小細胞肺癌患者における免疫チェックポイント阻害薬による消化管irAEにおけるヒト・腸内細菌叢の病態と炎症性腸疾患の類似性に関する検討

  西尾和人; 坂井和子; 櫻井俊治; 上嶋一臣; 永井知行; 林秀敏; 川上尚人; 高濱隆幸; 武田真幸; 中川和彦  肺癌(Web)  60-  (2)  2020
• CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討

  加藤了資; 林秀敏; 原谷浩司; 高濱隆幸; 谷崎潤子; 野長瀬祥兼; 田中薫; 吉田健史; 武田真幸; 米阪仁雄; 中川和彦; 坂井和子; 西尾和人; 高濱隆幸; 谷崎潤子; 野長瀬祥兼; 金田裕靖  肺癌(Web)  60-  (2)  2020
• Disease monitoring of circulating tumor DNA in EGFR T790M mutation positive NSCLC patients receiving treatment with osimertinib (WJOG8815L)

  坂井和子; 高濱隆幸; 東公一; 武田真幸; 岡本勇; 小野哲; 中川和彦; 西尾和人  日本がん分子標的治療学会学術集会プログラム・抄録集  24th-  2020
• The practice of planning and conducting investigator-initiated clinical trials

  高濱隆幸  日本呼吸器学会誌(Web)  9-  2020
• BAL診断でEGFR変異を診断しえた1例

  藤田 悦生; 林 未統; 前倉 俊治; 星屋 博信; 山本 勝廣; 古川 健一; 嶋田 浩介; 高濱 隆幸; 御勢 久也; 東田 有智  和歌山医学  70-  (4)  172  -172  2019/12
• 実臨床におけるリキッドバイオプシーの役割 CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討

  加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦  肺癌  59-  (6)  575  -575  2019/11
• EGFR変異陽性肺癌におけるHER3リガンド・ヘレグリン発現とEGFR-TKIの治療効果との関係

  米阪 仁雄; 岩間 映二; 林 秀敏; 高濱 隆幸; 谷崎 潤子; 武田 真幸; 東 公一; 安宅 信二; 岡本 勇; 中川 和彦  肺癌  59-  (6)  723  -723  2019/11
• EGFR-TKI治療前のEGFR遺伝子変異陽性NSCLCにおける別の遺伝子変異の存在が治療後のT790M遺伝子変異状態に及ぼす影響(Impact of Co-Mutations in EGFR-Mutated NSCLC Before EGFR-TKIs on T790M Mutation Status After TKIs)

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 原谷 浩司; 高濱 隆幸; 加藤 了資; 米阪 仁雄; 西尾 和人; 中川 和彦  肺癌  59-  (6)  723  -723  2019/11
• 固形がんに対する腫瘍遺伝子網羅的解析結果に関する観察研究

  杉本 藍; 福井 朋也; 佐々木 治一郎; 石原 未希子; 日吉 康弘; 井川 聡; 坂井 和子; 武田 真幸; 高濱 隆幸; 中川 和彦; 西尾 和人; 猶木 克彦  肺癌  59-  (6)  765  -765  2019/11
• EGFR変異陽性肺癌におけるHER3リガンド・ヘレグリン発現とEGFR-TKIの治療効果との関係

  米阪 仁雄; 岩間 映二; 林 秀敏; 高濱 隆幸; 谷崎 潤子; 武田 真幸; 東 公一; 安宅 信二; 岡本 勇; 中川 和彦  肺癌  59-  (6)  723  -723  2019/11
• 実臨床におけるリキッドバイオプシーの役割 CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討

  加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦  肺癌  59-  (6)  575  -575  2019/11
• Impact of Co-Mutations in EGFR-Mutated NSCLC Before EGFR-TKIs on T790M Mutation Status After TKIs(和訳中)

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 原谷 浩司; 高濱 隆幸; 加藤 了資; 米阪 仁雄; 西尾 和人; 中川 和彦  肺癌  59-  (6)  723  -723  2019/11
• 固形がんに対する腫瘍遺伝子網羅的解析結果に関する観察研究

  杉本 藍; 福井 朋也; 佐々木 治一郎; 石原 未希子; 日吉 康弘; 井川 聡; 坂井 和子; 武田 真幸; 高濱 隆幸; 中川 和彦; 西尾 和人; 猶木 克彦  肺癌  59-  (6)  765  -765  2019/11
• Current status and prospects of the relationship between core and corporative hospitals in precision medicine

  高濱 隆幸  呼吸器内科  36-  (3)  300  -304  2019/09
• PD-L1発現陰性/TMB Highの肺腺癌に対して化学療法とペムブロリズマブの併用療法を施行した1例

  金村 宙昌; 林 秀敏; 武田 真幸; 高濱 隆幸; 田中 薫; 中川 和彦; 坂井 和子; 西尾 和人  肺癌  59-  (4)  413  -414  2019/08
• PD-L1発現陰性/TMB Highの肺腺癌に対して化学療法とペムブロリズマブの併用療法を施行した1例

  金村 宙昌; 林 秀敏; 武田 真幸; 高濱 隆幸; 田中 薫; 中川 和彦; 坂井 和子; 西尾 和人  肺癌  59-  (4)  413  -414  2019/08
• EGFR T790M変異検査 リキッドバイオプシーとしての保険承認から今後の必要性まで

  高濱 隆幸  がん分子標的治療  17-  (1)  92  -95  2019/06
• 当院におけるオシメルチニブの使用成績と血漿中cfDNAの有用性に関する検討

  加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 谷崎 潤子; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 中川 和彦; 清水 重喜; 伊藤 彰彦; 坂井 和子; 西尾 和人  肺癌  59-  (2)  194  -194  2019/04
• 【肺癌 免疫・ゲノム医療で急展開する肺癌治療】最新の実地診療のポイントと整理 次世代シークエンサーを用いた遺伝子検査(組織)

  高濱 隆幸; 林 秀敏  Medical Practice  36-  (2)  241  -245  2019/02
• Alectinibによる長期の腫瘍制御が可能であった末期腎不全合併ALK融合遺伝子陽性肺腺癌の1例

  鈴木 慎一郎; 原谷 浩司; 渡邉 諭美; 高濱 隆幸; 武川 直樹; 林 秀敏; 武田 真幸; 米阪 仁雄; 中川 和彦  日本内科学会雑誌  108-  (Suppl.)  283  -283  2019/02
• PD-L1発現陰性/TMB Highの肺腺癌に対して化学療法とペムブロリズマブの併用療法を施行した1例

  金村宙昌; 林秀敏; 武田真幸; 高濱隆幸; 田中薫; 中川和彦; 高濱隆幸; 坂井和子; 西尾和人  肺癌(Web)  59-  (4)  2019
• 当院におけるオシメルチニブの使用成績と血漿中cfDNAの有用性に関する検討

  加藤了資; 林秀敏; 米阪仁雄; 原谷浩司; 酒井瞳; 高濱隆幸; 谷崎潤子; 岩朝勤; 田中薫; 吉田健史; 武田真幸; 金田裕靖; 中川和彦; 清水重喜; 伊藤彰彦; 坂井和子; 西尾和人  肺癌(Web)  59-  (2)  2019
• リキッドバイオプシーのup to date 血漿EGFR T790M遺伝子変異陽性非小細胞肺癌に対するosimertinibの有効性を検討する第二相試験

  東 公一; 下川 元継; 高濱 隆幸; 加藤 晃史; 駄賀 晴子; 岡本 勇; 赤松 弘朗; 高橋 利明; 大平 達夫; 横山 俊秀; 山本 信之; 西尾 和人; 中川 和彦  肺癌  58-  (6)  448  -448  2018/10
• 非小細胞肺癌における免疫チェックポイント阻害剤再投与の安全性と効果に関する後方視検討

  高濱 隆幸; 武田 真幸; 林 秀敏; 米阪 仁雄; 田中 薫; 岩朝 勤; 吉田 健史; 原谷 浩司; 加藤 了資; 鈴木 慎一郎  肺癌  58-  (6)  699  -699  2018/10
• 希少肺癌(Ret、ROS1、BRAF陽性)の治療 EGFRまたはHER2のエクソン20遺伝子変異を有する非小細胞肺癌の臨床的特徴(Clinical characteristics of non-small cell lung cancer harboring exon 20 mutation of EGFR or HER2)

  武田 真幸; 坂井 和子; 林 秀敏; 高濱 隆幸; 田中 薫; 西尾 和人; 中川 和彦  肺癌  58-  (6)  451  -451  2018/10
• 当院におけるオシメルチニブの使用成績と血漿中cfDNAの有用性に関する検討

  加藤 了資; 林 秀敏; 米阪 仁雄; 原谷 浩司; 酒井 瞳; 高濱 隆幸; 谷崎 潤子; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 金田 裕靖; 清水 重喜; 坂井 和子; 伊藤 彰彦; 西尾 和人; 中川 和彦  肺癌  58-  (6)  519  -519  2018/10
• 肺癌個別化医療に向けた取り組み

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 原谷 浩司; 福岡 和也; 中川 和彦; 西尾 和人  日本癌治療学会学術集会抄録集  56回-  O2  -2  2018/10
• 【オンコ・ジェネラリスト-「がん」に強い総合診療医をめざして】診断コラム どこまで検査すれば「原発不明がん」になるの?

  高濱 隆幸  総合診療  28-  (9)  1212  -1213  2018/09
• Relationship between checkpoint molecule B7-H3 and refractoriness to anti-PD-1 therapy in non-small cell lung cancer.

  Kimio Yonesaka; Keita Kudo; Shiki Takamura; Hitomi Sakai; Ryoji Kato; Koji Haratani; Takayuki Takahama; Kaoru Tanaka; Hidetoshi Hayashi; Hiroyuki Kaneda; Masayuki Takeda; Osamu Maenishi; Michiko Yamato; Masaaki Miyazawa; Kazuto Nishio; Kazuhiko Nakagawa  JOURNAL OF CLINICAL ONCOLOGY  36-  (15)  2018/05
• 研修医からの質問 Q&A 胃がんに対する治療で、分子標的治療薬と他の抗がん薬(ドセタキセルなど)を併用している場合、分子標的治療薬の効果低下(抵抗性出現)をどうやって判定するのでしょうか?

  高濱 隆幸  臨床腫瘍プラクティス  14-  (2)  151  -151  2018/05
• EGFR遺伝子変異陽性肺癌における血漿検体と組織検体でのT790M変異検査の比較検討

  田中薫; 加藤了資; 高濱隆幸; 谷崎潤子; 岩朝勤; 林秀敏; 武田真幸; 中川和彦  気管支学  40-  (Suppl.)  S239  -S239  2018/05
• Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.

  Masayuki Takeda; Kazuko Sakai; Hidetoshi Hayashi; Kaoru Tanaka; Junko Tanizaki; Takayuki Takahama; Koji Haratani; Kazuto Nishio; Kazuhiko Nakagawa  Oncotarget  9-  (30)  21132  -21140  2018/04  [Refereed]
  
• 固形癌に対する腫瘍遺伝子網羅的解析結果に基づく分子標的治療薬選択が与える影響

  高濱隆幸; 高濱隆幸; 武田真幸; 坂井和子; 中川和彦; 西尾和人  日本がん分子標的治療学会学術集会プログラム・抄録集  22nd-  79  2018/04
• 腸内細菌叢と腸管炎症・がん化のインタラクションに関する検討

  澤田貴宏; 中村有貴; 高濱隆幸; 坂井和子; 横山省三; 山上裕機; 西尾和人  日本がん分子標的治療学会学術集会プログラム・抄録集  22nd-  147  2018/04
• CAPP seqのもたらすリキッドバイオプシーの可能性と臨床応用の展望

  高濱隆幸; 高濱隆幸; 坂井和子; 中川和彦; 西尾和人  日本臨床腫瘍学会学術集会(CD-ROM)  16th-  2018
• 血漿EGFR T790M遺伝子変異陽性/既治療非小細胞肺癌患者におけるosimertinibの有効性を検討する第二相試験(WJOG8815L/LPS)

  高濱隆幸; 高濱隆幸; 東公一; 下川元継; 加藤晃史; 駄賀晴子; 岡本勇; 赤松弘朗; 高橋利明; 大平達夫; 横山俊秀; 平野勝也; 白石祥理; 姫路大輔; 山本信之; 西尾和人; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  16th-  2018
• 原発不明がんにおける腫瘍微小免疫環境と予後の関連性

  原谷浩司; 林秀敏; 高濱隆幸; 澤田貴宏; 中村靖司; 伊藤彰彦; 千葉康敬; 谷崎潤子; 藤田至彦; 坂井和子; 西尾和人; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  16th-  2018
• heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ,トラスツズマブ,T‐DM1の感受性に関する研究

  野長瀬祥兼; 米阪仁雄; 川上尚人; 渡邉諭美; 原谷浩司; 高濱隆幸; 武川直樹; 植田勲人; 谷崎潤子; 林秀俊; 吉田健史; 武田真幸; 千葉康敬; 中川和彦; 鶴谷純司  近畿大学医学雑誌  42-  (3-4)  25A  -25A  2017/12
• Future perspective on clinical trials using liquid biopsies from the standpoint of academia.

  高濱隆幸  月刊腫瘍内科  20-  (5)  515‐518  2017/11
• 注目の新薬 キイトルーダ(ペムブロリズマブ)

  原谷 浩司; 林 秀敏  診断と治療 = Diagnosis and treatment  105-  (11)  1465  -1470  2017/11
• がん治療における革新的変化を踏まえた最先端技術と新たな開発戦略の現状、今後の方向性 リキッドバイオプシーを用いた臨床試験・開発治験の諸問題・今後の展望 アカデミアの立場から

  高濱 隆幸  腫瘍内科  20-  (5)  515  -518  2017/11
• Future perspective on clinical trials using liquid biopsies from the standpoint of academia

  高濱 隆幸  腫瘍内科 = Clinical oncology  20-  (5)  515  -518  2017/11
• 扁平上皮肺癌のアクショナブルな遺伝子異常

  西尾和人; 金田裕靖; 谷崎潤子; 坂井和子; 高濱隆幸; 高濱隆幸; 武田真幸; 光冨徹哉; 中川和彦; 岡本勇  日本肺癌学会総会号  58th-  371  2017/09
• 扁平上皮肺癌に対する薬物療法 新たな展開 扁平上皮肺癌のアクショナブルな遺伝子異常

  西尾 和人; 金田 裕靖; 谷崎 潤子; 坂井 和子; 高濱 隆幸; 武田 真幸; 光冨 徹哉; 中川 和彦; 岡本 勇  肺癌  57-  (5)  371  -371  2017/09
• heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ、トラスツズマブ、T-DM1の感受性に関する研究

  野長瀬 祥兼; 米阪 仁雄; 川上 尚人; 渡邉 諭美; 原谷 浩司; 高濱 隆幸; 武川 直樹; 植田 勲人; 谷崎 潤子; 林 秀敏; 吉田 健史; 武田 真幸; 千葉 康敬; 田村 孝雄; 中川 和彦; 鶴谷 純司  日本乳癌学会総会プログラム抄録集  25回-  (3)  559  -559  2017/07
• ニボルマブによるirAE対応に向けた院内体制構築の試み

  米本 加奈子; 荒木 順子; 森脇 静; 西山 登志子; 太田 文典; 高濱 隆幸  肺癌  57-  (3)  250  -250  2017/06
• 肺癌患者の診断から在宅療養と継続した支援の取り組み

  西林 和美; 藤木 智子; 宮内 豊路子; 西山 登志子; 藤田 悦生; 太田 典文; 高濱 隆幸  肺癌  57-  (3)  250  -250  2017/06
• Pleural effusionで発症しMesotheliomaと診断できた2例

  藤田 悦生; 太田 文典; 清井 めぐみ; 庄嶋 健作; 川畑 仁貴; 青木 達也; 川端 大輝; 橋本 忠幸; 阪中 啓一郎; 仲地 健一郎; 阪中 謙司; 鷺森 美希; 山村 理沙; 北村 要輔; 山口 雄大; 上村 和久; 山下 実輝; 流田 智史; 高濱 隆幸; 坂田 好史; 稲田 佳紀; 小澤 悟; 小林 良平; 嶋田 浩介; 寒川 浩道; 高畑 昌弘; 匹本 樹寿; 小林 克暢; 星屋 博信; 山本 勝廣  肺癌  57-  (3)  252  -252  2017/06
• 進行非小細胞肺癌に対する微量心嚢水の予後に関する検討

  加藤 了資; 林 秀敏; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 岩朝 勤; 田中 薫; 武田 真幸; 中川 和彦; 千葉 康敬  肺癌  57-  (3)  253  -253  2017/06
• 組織型転化を来したEGFR陽性肺癌症例の臨床的検討

  田中薫; 加藤了資; 原谷浩司; 高濱隆幸; 岩朝勤; 林秀敏; 武田真幸; 清水重喜; 伊藤彰彦; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  57-  (3)  243  -244  2017/06
• Biomarker diagnostics in non-small cell lung cancer

  高濱隆幸; 光冨徹哉  月刊腫瘍内科  19-  (5)  512  -518  2017/05
• Biomarker diagnostics in non-small cell lung cancer

  高濱 隆幸; 光冨 徹哉  腫瘍内科 = Clinical oncology  19-  (5)  512  -518  2017/05
• Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)

  Koichi Azuma; Takayuki Takahama; Kazuko Sakai; Masayuki Takeda; Toyoaki Hida; Masataka Hirabayashi; Tetsuya Oguri; Hiroshi Tanaka; Noriyuki Ebi; Toshiyuki Sawa; Akihiro Bessho; Motoko Tachihara; Hiroaki Akamatsu; Shuji Bandoh; Daisuke Himeji; Tatsuo Ohira; Mototsugu Shimokawa; Nobuyuki Yamamoto; Yoichi Nakanishi; Kazuhiko Nakagawa; Kazuto Nishio  JOURNAL OF THORACIC ONCOLOGY  12-  (1)  S389  -S390  2017/01
• heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ,トラスツズマブ,T‐DM1の感受性に関する研究

  野長瀬祥兼; 米阪仁雄; 川上尚人; 渡邉諭美; 原谷浩司; 高濱隆幸; 武川直樹; 植田勲人; 谷崎潤子; 林秀敏; 吉田健史; 武田真幸; 千葉康敬; 田村孝雄; 中川和彦; 鶴谷純司  日本乳癌学会学術総会プログラム・抄録集  25th-  559  2017
• 固形癌に対する腫瘍遺伝子網羅的解析結果に基づく分子標的治療薬選択に関する研究

  高濱隆幸; 武田真幸; 清水俊雄; 坂井和子; 田中薫; 野長瀬祥兼; 原谷浩司; 鶴谷純司; 西尾和人; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  15th-  ROMBUNNO.O1‐2‐6  2017
• 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例

  加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司  肺癌  56-  (7)  1072  -1072  2016/12
• 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例

  加藤 了資; 酒井 瞳; 原谷 浩司; 高濱 隆幸; 谷崎 潤子; 吉田 健史; 岩朝 勤; 田中 薫; 林 秀敏; 武田 真幸; 中川 和彦; 古川 健太郎; 奥田 武司  肺癌  56-  (7)  1072  -1072  2016/12
• 尿崩症を初発症状とした肺小細胞癌下垂体転移の1例

  加藤了資; 酒井瞳; 原谷浩司; 高濱隆幸; 谷崎潤子; 吉田健史; 岩朝勤; 田中薫; 林秀敏; 武田真幸; 中川和彦; 古川健太郎; 奥田武司  肺癌(Web)  56-  (7)  1072(J‐STAGE)  -1072  2016/12
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  武田真幸; 坂井和子; 林秀敏; 田中薫; 吉田健史; 岩朝勤; 高濱隆幸; 野長瀬祥兼; 西尾和人; 中川和彦  近畿大学医学雑誌  41-  (3-4)  19A  -19A  2016/12
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  武田真幸; 坂井和子; 林秀敏; 田中薫; 吉田健史; 岩朝勤; 高濱隆幸; 野長瀬祥兼; 西尾和人; 中川和彦  日本肺癌学会総会号  56-  (6)  637  -637  2016/11
• 組織型転化を来したEGFR・ALK陽性肺癌症例の臨床的検討

  田中薫; 谷崎潤子; 加藤了資; 原谷浩司; 武川直樹; 高濱隆幸; 岩朝勤; 林秀敏; 武田真幸; 中川和彦  日本肺癌学会総会号  56-  (6)  572  -572  2016/11
• ニボルマブ治療によりpseudoprogressionを認めた肺腺癌の2例

  谷崎潤子; 林秀敏; 加藤了資; 原谷浩司; 高濱隆幸; 田中薫; 岩朝勤; 武田真幸; 中川和彦  日本肺癌学会総会号  56-  (6)  569  -569  2016/11
• 間質性肺炎合併 肺癌での呼吸不全でパルス療法,緩和ケアを導入した1例

  藤田悦生; 松野正平; 庄嶋健作; 星屋博信; 山本勝廣; 太田文典; 清井めぐみ; 阪中謙司; 北村要輔; 高濱隆幸; 河原正明; 嶋田浩介  日本肺癌学会総会号  56-  (6)  861  -861  2016/11
• 血漿遊離DNAからT790M遺伝子変異陽性の確認された患者に対する第三世代EGFRTKIを用いた第II相試験の計画

  高濱隆幸; 坂井和子; 山本信之; 西尾和人; 中川和彦  日本肺癌学会総会号  56-  (6)  555  -555  2016/11
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 吉田 健史; 岩朝 勤; 光冨 徹哉; 伊藤 彰彦; 西尾 和人; 中川 和彦  日本癌学会総会記事  75回-  J  -1063  2016/10
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  武田 真幸; 坂井 和子; 林 秀敏; 田中 薫; 高濱 隆幸; 吉田 健史; 岩朝 勤; 光冨 徹哉; 伊藤 彰彦; 西尾 和人; 中川 和彦  日本癌学会総会記事  75回-  J  -1063  2016/10
• Heregulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vivo

  Yoshikane Nonagase; Kimio Yonesaka; Satomi Watanabe; Koji Haratani; Takayuki Takahama; Naoki Takegawa; Hiroto Ueda; Hisato Kawakami; Hidetoshi Hayashi; Masayuki Takeda; Haruka Sakamoto; Takao Tamura; Kazuhiko Nakagawa; Junji Tsurutani  CANCER RESEARCH  76-  2016/07
• Clinical use of ALK inhibitor

  原谷 浩司; 中川 和彦  腫瘍内科 = Clinical oncology  17-  (6)  641  -648  2016/06
• 下咽頭癌頸部リンパ節転移に対して先行頸部郭清術を施行した症例の検討

  北野睦三; 木村隆幸; 西原美沙子; 白石功; 森川大樹; 小林孝光; 速水康介; 藤原良平; 石川一樹; 横川正樹; 高濱隆幸; 吉田健史; 林秀敏; 田中薫; 土井勝美  頭けい部癌  42-  (2)  170  2016/05
• 下咽頭癌頸部リンパ節転移に対して先行頸部郭清術を施行した症例の検討

  北野 睦三; 木村 隆幸; 西原 美沙子; 白石 功; 森川 大樹; 小林 孝光; 速水 康介; 藤原 良平; 石川 一樹; 横川 正樹; 高濱 隆幸; 吉田 健史; 林 秀敏; 田中 薫; 土井 勝美  頭頸部癌  42-  (2)  170  -170  2016/05
• Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

  N. Takegawa; H. Hayashi; N. Iizuka; T. Takahama; H. Ueda; K. Tanaka; M. Takeda; K. Nakagawa  ANNALS OF ONCOLOGY  27-  (5)  953  -955  2016/05
• Afatinib抵抗性の脳転移を有するEGFR変異陽性進行非小細胞肺癌に対して全脳照射後にErlotinibが長期奏効した1例

  野長瀬 祥兼; 渡邉 諭美; 原谷 浩司; 高濱 隆幸; 武川 直樹; 植田 勲人; 田村 孝雄; 中川 和彦; 岡本 邦男  肺癌  56-  (2)  138  -138  2016/04
• アレクチニブ耐性後に小細胞癌転化をしたALK融合遺伝子陽性の肺腺癌の一例

  武川直樹; 林秀敏; 飯塚徳重; 高濱隆幸; 植田勲人; 田中薫; 武田真幸; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  14th-  ROMBUNNO.PF1‐032  2016
• Afatinib抵抗性の脳転移を有するEGFR変異陽性進行非小細胞肺癌に対して全脳照射後にErlotinibが長期奏効した1例

  野長瀬祥兼; 渡邉諭美; 原谷浩司; 高濱隆幸; 武川直樹; 植田勲人; 田村孝雄; 中川和彦; 岡本邦男  肺癌(Web)  56-  (2)  138(J‐STAGE)  2016
• Successful treatment with HER2-targeting therapy beyond progression for HER2-positive Extramammary Paget's disease

  WATANABE Satomi; TAKEDA Masayuki; TAKAHAMA Takayuki; TANIZAKI Junko; IWASA Tsutomu; TSURUTANI Junji; HAYASHI Hidetoshi; SHIMIZU Toshio; WADA Yoshitaka; NAKAGAWA Kazuhiko  日本臨床腫瘍学会学術集会(CD-ROM)  14th-  ROMBUNNO.PF1‐045  2016
• Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer

  TAKEDA Masayuki; SAKAI Kazuko; HAYASHI Hidetoshi; TANAKA Kaoru; TAKAHAMA Takayuki; YOSHIDA Takeshi; IWASA Tsutomu; MITSUDOMI Tetsuya; ITO Akihiko; NISHIO Kazuto; NAKAGAWA Kazuhiko  日本癌学会学術総会抄録集(Web)  75th-  ROMBUNNO.J‐1063 (WEB ONLY)  2016
• Cell free DNAの可能性

  TAKAHAMA TAKAYUKI  がん分子標的治療  13-  (4)  496  -499  2016/01
• Afatinib抵抗性の脳転移を有するEGFR変異陽性進行非小細胞肺癌に対してErlotinibが長期奏効した一例

  野長瀬 祥兼; 岡本 邦男; 西田 諭美; 原谷 浩司; 高濱 隆幸; 武川 直樹; 植田 勲人; 田村 孝雄; 中川 和彦  肺癌  55-  (5)  486  -486  2015/10
• ALK+NSCLCにおける初期進行後のcrizotinib療法継続の臨床的有益性(Clinical benefit of continued therapy with crizotinib beyond initial progression in ALK + NSCLC)

  金田 裕靖; 武田 真幸; 田中 薫; 吉田 健史; 岩朝 勤; 岡本 邦男; 高濱 隆幸; 清水 俊雄; 中川 和彦  肺癌  55-  (5)  466  -466  2015/10
• 当院における非小細胞肺癌に対するre‐biopsyの検討

  TANAKA KAORU; NISHIDA YUMI; HARATANI KOJI; NONAGASE YOSHIKANE; TAKAHAMA TAKAYUKI; YOSHIDA TAKESHI; IWASA TSUTOMU; HAYASHI HIDETOSHI; TAKEDA MASAYUKI; KANEDA HIROYASU; NAKAGAWA KAZUHIKO  日本肺癌学会総会号  55-  (5)  547  -547  2015/10
• EGFR遺伝子変異陽性肺癌に対する血漿中cell free DNAを用いたT790M変異検出の臨床的有用性試験WJOG8014LTR

  TAKAHAMA TAKAYUKI; SAKAI KAZUKO; AZUMA KOICHI; HIDA TOYOAKI; HIRANO KATSUYA; NIIMI AKIO; TANAKA HIROSHI; EBI NORIYUKI; SAWA TOSHIYUKI; BESSHO AKIHIRO; TACHIHARA MOTOKO; SHIMOKAWA MOTOTSUGU; NAKAGAWA KAZUHIKO; NAKANISHI YOICHI; NISHIO KAZUTO  日本肺癌学会総会号  55-  (5)  468  -468  2015/10
• ALK阻害剤による治療後に小細胞肺癌・扁平上皮癌への形質転換を認めたALK融合遺伝子陽性肺癌の1例

  MUKAWA NAOKI; NAKAGAWA KAZUHIKO; TSURUTANI JUNSHI; SHIMIZU TOSHIO; TAKEDA MASAYUKI; TANAKA KAORU; IWASA TSUTOMU; YOSHIDA TAKESHI; HAYASHI HIDETOSHI; TANIZAKI JUNKO; TAKAHAMA TAKAYUKI; HARATANI KOJI; NISHIDA YUMI  日本肺癌学会総会号  55-  (5)  661  -661  2015/10
• EGFR遺伝子変異型非小細胞肺癌におけるアファニチブによるEGFR阻害剤への耐性克服治療について

  YONESAKA YOSHIO; YONESAKA YOSHIO; KUDO KEITA; NISHIDA YUMI; TAKAHAMA TAKAYUKI; TAKEDA MASAYUKI; KANEDA HIROYASU; NAKAGAWA KAZUHIKO  日本肺癌学会総会号  55-  (5)  399  -399  2015/10
• Clinical benefit of continued therapy with crizotinib beyond initial progression in ALK + NSCLC(和訳中)

  金田 裕靖; 武田 真幸; 田中 薫; 吉田 健史; 岩朝 勤; 岡本 邦男; 高濱 隆幸; 清水 俊雄; 中川 和彦  肺癌  55-  (5)  466  -466  2015/10
• Afatinib抵抗性の脳転移を有するEGFR変異陽性進行非小細胞肺癌に対してErlotinibが長期奏効した一例

  野長瀬 祥兼; 岡本 邦男; 西田 諭美; 原谷 浩司; 高濱 隆幸; 武川 直樹; 植田 勲人; 田村 孝雄; 中川 和彦  肺癌  55-  (5)  486  -486  2015/10
• 3. 当院における非小細胞肺癌に対するre-biopsyの検討(第97回 日本呼吸器内視鏡学会近畿支部会)

  田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 金田 裕靖; 中川 和彦  気管支学 : 日本気管支研究会雑誌  37-  (5)  2015/09
• 当院における非小細胞肺癌に対するre-biopsyの検討

  田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 金田 裕靖; 中川 和彦  気管支学  37-  (5)  607  -607  2015/09
• Fibrosisに合併したLung cancerの2例

  FUJITA ETSUO; IKEDA KYOHEI; SAKANAKA KENJI; TONO NOBUYUKI; OKADA KAZUYA; KAWAHATA HITOTAKA; HASHIMOTO TADAYUKI; ITO HIDEYUKI; OTA FUMINORI; KIYOI MEGUMI; KOBAYASHI KATSUNOBU; SAMUKAWA HIROMICHI; TAKAHATA MASAHIRO; YAMAMOTO YASUNORI; HOSHIYA HIRONOBU; NAGAREDA TOMOFUMI; INADA YOSHINORI; SAKATA YOSHIFUMI; SHIMADA KOSUKE; HATTORI MAIKO; KAWAHARA MASAAKI; TAKAHAMA TAKAYUKI; NAKAGAWA KAZUHIKO; NAKANISHI YUYA; NISHIKAWA YUSAKU; TODA YUJI; YAMAMOTO KATSUHIRO  和歌山医学  66-  (3)  107  -108  2015/09
• 当院における非小細胞肺癌に対するre-biopsyの検討

  田中 薫; 西田 諭美; 原谷 浩司; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 林 秀敏; 武田 真幸; 中川 和彦; 金田 裕靖  肺癌  55-  (4)  306  -307  2015/08
• 肺癌における次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  谷崎 潤子; 武田 真幸; 清水 俊雄; 金田 裕靖; 田中 薫; 岩朝 勤; 吉田 健史; 高濱 隆幸; 中川 和彦; 坂井 和子; 西尾 和人  肺癌  55-  (4)  311  -311  2015/08
• Alectinibによる治療後に小細胞肺癌・扁平上皮癌への形質転換を認めたALK融合遺伝子陽性肺癌の1例

  高濱 隆幸; 林 秀敏; 武川 直樹; 植田 勲人; 吉田 健史; 岩朝 勤; 田中 薫; 武田 真幸; 中川 和彦  肺癌  55-  (4)  316  -316  2015/08
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  TAKEDA MASAYUKI; SAKAI KAZUKO; TANAKA KAORU; YOSHIDA TAKESHI; IWASA TSUTOMU; TAKAHAMA TAKAYUKI; NONAGASE YOSHIKANE; OKABE TAKAKI; HAYASHI HIDETOSHI; OKAMOTO KUNIO; KANEDA HIROYASU; SHIMIZU TOSHIO; NISHIO KAZUTO; NAKAGAWA KAZUHIKO  日本呼吸器学会誌  4-  (増刊)  146  -146  2015/03
• EGFR-TKI既治療のEGFR遺伝子変異陽性NSCLCに対してアファチニブを使用した1例

  西田 諭美; 工藤 慶太; 金田 裕靖; 高濱 隆幸; 岩朝 勤; 田中 薫; 吉田 健史; 武田 真幸; 清水 俊雄; 中川 和彦  肺癌  55-  (1)  71  -71  2015/02
• 化学療法中に間質性肺炎増悪を来した肺癌患者転帰の後ろ向き検討

  TAKAHAMA TAKAYUKI; KANEDA HIROYASU; TANAKA KAORU; KUDO KEITA; IWASA TSUTOMU; YOSHIDA TAKESHI; TAKEDA MASAYUKI; SHIMIZU TOSHIO; TSURUTANI JUNJI; NAKAGAWA KAZUHIKO  日本内科学会雑誌  104-  (Suppl.)  242  -242  2015/02
• EGFR遺伝子変異陽性非小細胞肺癌に対するerlotinibの初回治療における有用性の検討

  NISHIDA SATOMI; KANEDA HIROYASU; KUDO KEITA; TAKAHAMA TAKAYUKI; IWASA TSUTOMU; TANAKA KAORU; YOSHIDA TAKESHI; TAKEDA MASAYUKI; SHIMIZU TOSHIO; NAKAGAWA KAZUHIKO  日本内科学会雑誌  104-  (Suppl.)  191  -191  2015/02
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  TAKEDA MASAYUKI; SHIMIZU TOSHIO; KANEDA HIROYASU; TANAKA KAORU; IWASA TSUTOMU; YOSHIDA TAKESHI; TAKAHAMA TAKAYUKI; SAKAI KAZUKO; NISHIO KAZUTO; NAKAGAWA KAZUHIKO  日本内科学会雑誌  104-  (Suppl.)  236  -236  2015/02
• 肺癌における次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  谷崎潤子; 武田真幸; 清水俊雄; 金田裕靖; 田中薫; 岩朝勤; 吉田健史; 高濱隆幸; 中川和彦; 坂井和子; 西尾和人  肺癌(Web)  55-  (4)  2015
• EGFR‐TKI既治療のEGFR遺伝子変異陽性NSCLCに対してアファチニブを使用した1例

  西田諭美; 工藤慶太; 金田裕靖; 高濱隆幸; 岩朝勤; 田中薫; 吉田健史; 武田真幸; 清水俊雄; 中川和彦  肺癌(Web)  55-  (1)  71(J‐STAGE)  2015
• Alectinibによる治療後に小細胞肺癌・扁平上皮癌への形質転換を認めたALK融合遺伝子陽性肺癌の1例

  高濱隆幸; 林秀敏; 武川直樹; 植田勲人; 吉田健史; 岩朝勤; 田中薫; 武田真幸; 中川和彦  肺癌(Web)  55-  (4)  316(J‐STAGE)  2015
• 原発不明のがん性胸膜炎に対し胸腔鏡下胸膜生検で再発乳がんの確定診断に至った症例

  MIYAGAWA CHIHO; TANAKA KAORU; NISHIDA SATOMI; NONASE YOSHIKANE; TAKAHAMA TAKAYUKI; YOSHIDA TAKESHI; IWASA TSUTOMU; KUDO KEITA; TAKEDA MASAYUKI; KANEDA HIROYASU; TSURUTANI JUNJI; NAKAGAWA KAZUHIKO  気管支学  37-  (1)  114  -115  2015/01
• 10.原発不明のがん性胸膜炎に対し胸腔鏡下胸膜生検で再発乳がんの確定診断に至った症例(第96回 日本呼吸器内視鏡学会近畿支部会)

  宮川 知保; 金田 裕靖; 鶴谷 純司; 中川 和彦; 田中 薫; 西田 諭美; 野長瀬 祥兼; 高濱 隆幸; 吉田 健史; 岩朝 勤; 工藤 慶太; 武田 真幸  気管支学  37-  (1)  114  -115  2015
• Lung cancerの加療でGefitinibの効果を認めた2例

  HIGASHINO NOBUYUKI; FUJITA ETSUO; OTA FUMINORI; YADA YUMI; IGUCHI MASAE; OKADA KAZUYA; SAKANAKA KEIICHIRO; NIWA TOORU; OBOSHI TAKASHI; NAGAREDA TOMOFUMI; HIGUCHI HIROSHI; IKEDA KYOHEI; TAICHI RYO; KAKIMOTO NAOKI; SEIGAN MAKOTO; KAWAHARA MASAAKI; OKAMOTO KUNIO; TAKAHAMA TAKAYUKI; NAKAGAWA KAZUHIKO; NISHIKAWA YUSAKU; OKIMOTO NAMI; TODA YUJI; YAMAMOTO KATSUHIRO  和歌山医学  65-  (4)  153  -153  2014/12
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  TAKEDA Masayuki; SHIMIZU Toshio; TANAKA Kaoru; YOSHIDA Takeshi; IWAASA Tsutomu; TAKAHAMA Takayuki; NONAGASE Yoshikane; OKABE Takaki; HAYASHI Hidetoshi; OKAMOTO Kunio; SAKAI Kazuko; NISHIO Kazuto; NAKAGAWA Kazuhiko  日本肺癌学会総会号  55th-  364  2014/10
• EGFR遺伝子変異陽性非小細胞肺癌に対するerlotinibの初回治療における有用性の検討

  NISHIDA YUMI; KANEDA HIROYASU; KUDO KEITA; TANAKA KAORU; YOSHIDA TAKESHI; IWASA TSUTOMU; TAKAHAMA TAKAYUKI; TAKEDA MASAYUKI; SHIMIZU TOSHIO; NAKAGAWA KAZUHIKO  日本肺癌学会総会号  55th-  460  2014/10
• CLINICAL BENEFIT OF CONTINUED THERAPY WITH CRIZOTINIB BEYOND INITIAL DISEASE PROGRESSION IN ADVANCED ALK POSITIVE NSCLC

  Hiroyasu Kaneda; Masayuki Takeda; Kaoru Tanaka; Takeshi Yoshida; Tsutomu Iwasa; Kunio Okamoto; Hisato Kawakami; Takayuki Takahama; Toshio Shimizu; Kazuhiko Nakagawa  ANNALS OF ONCOLOGY  25-  ROMBUNNO.O3-9-4  2014/10
• 化学療法中に間質性肺炎増悪を来した肺癌患者転帰の後ろ向き検討

  TAKAHAMA TAKAYUKI; KANEDA HIROYASU; TANAKA KAORU; UEDA KUNJI; NISHIDA SATOMI; MUKAWA NAOKI; NONAGASE YOSHIKANE; KUDO KEITA; IWASA TSUTOMU; YOSHIDA TAKESHI; TAKEDA MASAYUKI; SHIMIZU TOSHIO; TSURUTANI JUNSHI; TAMURA TAKAO; NAKAGAWA KAZUHIKO  日本肺癌学会総会号  54-  (5)  587  -587  2014/10
• 副腎転移巣の破裂,出血により急激な全身状態悪化を来した原発性肺扁平上皮癌の一例

  NAKADA YUKI; TAKAHAMA TAKAYUKI; TANAKA KAORU; UEDA KUNJI; NISHIDA SATOMI; MUKAWA NAOKI; NONAGASE YOSHIKANE; KUDO KEITA; IWASA TSUTOMU; YOSHIDA TAKESHI; TAKEDA MASAYUKI; KANEDA HIROYASU; SHIMIZU TOSHIO; TSURUTANI JUNSHI; TAMURA TAKAO; NAKAGAWA KAZUHIKO  日本肺癌学会総会号  54-  (5)  506  -506  2014/10
• 当院での胸部異常陰影,肺腫瘍を疑った時のatypical mycobacteriumの検出状況

  FUJITA ETSUO; SAKANAKA KEIICHIRO; NIWA TOORU; OKADA KAZUYA; IGUCHI MASAE; OBOSHI TAKASHI; SAMUKAWA HIROMICHI; HIGASHIDA TOMOE; KOBAYASHI KATSUNOBU; HOSHIYA HIRONOBU; OTA FUMINORI; YADA YUMI; KAWAHARA MASAAKI; TAKAHAMA TAKAYUKI; NAKAGAWA KAZUHIKO; NISHIKAWA YUSAKU; OKIMOTO NAMI; TODA YUJI; YAMAMOTO KATSUHIRO  日本肺癌学会総会号  54-  (5)  643  -643  2014/10
• 肺癌に於ける次世代シーケンサーを用いた変異解析に基づく分子標的薬適応決定

  武田 真幸; 清水 俊雄; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 野長瀬 祥兼; 岡部 崇記; 林 秀敏; 岡本 邦男; 坂井 和子; 西尾 和人; 中川 和彦  肺癌  54-  (5)  364  -364  2014/10
• EGFR遺伝子変異陽性非小細胞肺癌に対するerlotinibの初回治療における有用性の検討

  西田 諭美; 金田 裕靖; 工藤 慶太; 田中 薫; 吉田 健史; 岩朝 勤; 高濱 隆幸; 武田 真幸; 清水 俊雄; 中川 和彦  肺癌  54-  (5)  460  -460  2014/10
• 尿毒症性胸膜炎を発症した透析患者の1例

  ISE NATSUMI; YAMAZAKI KOJI; YAMAMOTO MAI; MITSUNAKA KOKI; TAKAHAMA TAKAYUKI; MIYAWAKI HIROSHI; YOSHIKAWA TAKESHI; MISAO TAKAHIKO  香川県内科医会誌  50-  29  -33  2014/08
• 尿毒症性胸膜炎を発症した透析患者の1例

  伊勢 奈津美; 山崎 康司; 山本 真衣; 光中 弘毅; 高濱 隆幸; 宮脇 裕史; 吉川 武志; 三竿 貴彦  香川県内科医会誌  50-  29  -33  2014/08
• 新薬の最近の話題 エルロチニブ

  TAKAHAMA TAKAYUKI; NONAGASE YOSHIKANE; NAKAGAWA KAZUHIKO  分子呼吸器病  18-  (1)  130  -135  2014/03
• 乳癌術後化学放射線療法中に二次性血液腫瘍を来した症例の検討

  高濱隆幸; 岩朝勤; 鶴谷純司; 新崎亘; 安積達也; 橋本幸彦; 菰池佳史; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  12th-  2014
• 膵癌,大腸癌の重複癌に対してSOX‐Bevacizumabが奏効した1例

  高濱隆幸; 野長瀬祥兼; 崎山勉; 川上尚人; 仁科慎一; 田村孝雄; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  12th-  ROMBUNNO.P2-12-6  2014
• 肝機能障害を呈する胃癌肝転移患者に対しカペシタビンとシスプラチン併用療法が安全かつ効果的に投与できた一例

  野長瀬祥兼; 崎山勉; 高濱隆幸; 川上尚人; 仁科慎一; 田村孝雄; 中川和彦  日本臨床腫瘍学会学術集会(CD-ROM)  12th-  ROMBUNNO.P1-30-2  2014
• Anaplastic lymphoma kinase gene analysis as a useful tool for identifying primary unknown metastatic lung adenocarcinoma

  Naoki Watanabe; Tomoya Ishii; Takayuki Takahama; Akira Tadokoro; Nobuhiro Kanaji; Hiroaki Dobashi; Shuji Bandoh  Internal Medicine  53-  (23)  2711  -2715  2014
• EGFR遺伝子変異陽性患者におけるEGFR阻害剤の耐性後の投与期間についての検討

  OKAMOTO KUNIO; HAYASHI HIDETOSHI; TAKAHAMA TAKAYUKI; FUMITA SOICHI; TANAKA KAORU; KATO MOTOKAZU; NAKAGAWA KAZUHIKO  日本臨床腫瘍学会学術集会(CD-ROM)  12th-  ROMBUNNO.P3-15-4  2014
• Development of companion diagnostics for EML4-ALK positive lung cancer

  高濱 隆幸; 清水 俊雄  腫瘍内科  12-  (6)  645  -651  2013/12
• 個別化医療を目的としたバイオマーカーのコンパニオン開発 Crizotinibにおけるコンパニオン診断薬の開発―ALK fusion protein

  高濱隆幸; 清水俊雄  月刊腫瘍内科  12-  (6)  645  -651  2013/12
• ステロイドパルス中にグラム陽性球桿菌Weissella confusaによる菌血症を発症した活動性SLEの一例

  渡邊 直樹; 根ヶ山 清; 大楠 清文; 高濱 隆幸; 石井 知也; 坂東 修二; 横田 恭子  感染症学雑誌  87-  (臨増)  293  -293  2013/05
• 肺癌細胞検体からのRET融合遺伝子,ROS1融合遺伝子及びBRAF遺伝子変異の検出

  金地伸拓; 田所明; 渡邊直樹; 高濱隆幸; 石井知也; 坂東修二; 松永卓也  日本呼吸器学会誌  2-  121  2013/03
• 肺癌 診断と病態生理 肺癌細胞検体からのRET融合遺伝子、ROS1融合遺伝子及びBRAF遺伝子変異の検出

  金地 伸拓; 田所 明; 渡邊 直樹; 高濱 隆幸; 石井 知也; 坂東 修二; 松永 卓也  日本呼吸器学会誌  2-  (増刊)  121  -121  2013/03
• 横隔神経麻痺で発見されたvenous aneurysmの1切除例

  安藤 里沙子; 小野 佐保子; 津村 朋子; 青江 基; 吉川 武志; 三竿 貴彦; 高濱 隆幸; 上田 裕; 宮脇 裕史  香川県立中央病院医学雑誌  32-  17  -21  2013/03
• 限局性pulmonary light chain deposition diseaseの1例

  高濱隆幸; 石井知也; 田所明; 渡邊直樹; 金地伸拓; 坂東修二; 羽場礼次; 垂水晋太郎; 横見瀬裕保; 松永卓也  日本呼吸器学会誌  2-  (増刊)  161  -161  2013/03
• iPat法により検出されたEGFRおよびALK遺伝子異常における治療効果の検討

  石井知也; 高濱隆幸; 田所明; 渡邊直樹; 金地伸拓; 坂東修二; 松永卓也  日本呼吸器学会誌  2-  (増刊)  231  -231  2013/03
• 肺放線菌症の臨床病理学的検討

  坂東修二; 渡邊直樹; 高濱隆幸; 金地伸拓; 石井知也; 松永卓也  日本内科学会雑誌  102-  (Suppl.)  178  -178  2013/02
• EGFR mutation identifies distant squamous cell carcinoma as metastasis from lung adenocarcinoma.

  KANAJI Nobuhiro; BANDOH Shuji; HAYASHI Toshitetsu; HABA Reiji; WATANABE Naoki; ISHII Tomoya; KUNITOMO Asako; TAKAHAMA Takayuki; TADOKORO Akira; IMATAKI Osamu; DOBASHI Hiroaki; MATSUNAGA Takuya  World J Respirol.  3-  (2)  38-43  2013  [Refereed]
  
• Paraneoplastic focal segmental glomerulosclerosis in a patient with lung adenocarcinoma

  Akira Tadokoro; Tomoya Ishii; Takayuki Takahama; Naoki Watanabe; Koshiro Takano; Nobuhiro Kanaji; Osamu Imataki; Hiroaki Dobashi; Shuji Bandoh; Takuya Matsunaga  Internal Medicine  52-  (17)  1953  -1956  2013
• Crizotinibにより食道潰瘍を来した肺腺癌の1例

  金地伸拓; 坂東修二; 石井知也; 渡邊直樹; 田所明; 高濱隆幸; 松永卓也  日本臨床腫瘍学会学術集会(CD-ROM)  11th-  ROMBUNNO.P3-079  2013
• A CASE OF LUNG ADENOCARCINOMA WITH WILD-TYPE EGFR MALIGNANT PLEURAL EFFUSION WELL CONTROLLED BY TREATMENT WITH GEFITINIB

  Y. Ueda; T. Takahama; K. Sakai; H. Miyawaki; T. Yoshikawa; T. Misao; M. Aoe; N. Kanaji; T. Ishii; S. Bandoh; T. Matsunaga  ANNALS OF ONCOLOGY  23-  146  -146  2012/10
• 巨大気腫性肺嚢胞切除後の遷延性肺瘻に対してEWSによる気管支充填術が有効であった1例

  小野 佐保子; 安藤 里沙子; 治田 賢; 青江 基; 吉川 武志; 三竿 貴彦; 高濱 隆幸; 上田 裕; 宮脇 裕史  香川県立中央病院医学雑誌  31-  21  -23  2012/03
• 約4年間、当院で経過観察された後に手術を行い、肺癌と確定診断された1例

  高塚 萌; 青江 基; 益田 智章; 吉川 武志; 三竿 貴彦; 高濱 隆幸; 上田 裕; 宮脇 裕史; 櫻井 淳; 淀谷 光子; 中村 聡子  香川県立中央病院医学雑誌  31-  27  -30  2012/03
• 肺腫瘤性病変に対する術中穿刺吸引細胞診:有用性と腫瘍細胞播種の危険性に関する検討

  三竿貴彦; 吉川武志; 青江基; 高濱隆幸; 上田裕; 宮脇裕史  肺癌  51-  (5)  575  -575  2011/10
• 気胸が先行した肺癌の3例

  吉川武志; 三竿貴彦; 青江基; 高濱隆幸; 上田裕; 宮脇裕史  肺癌  51-  (5)  596  -596  2011/10
• 当院での呼吸ケアサポートチーム(RST)の活動について

  青江基; 高濱隆幸  香川県医師会誌  64-  (特別)  60  -60  2011/09
• 当院で施行されたNuss法を用いた漏斗胸手術の2例

  益田智章; 高塚萌; 青江基; 吉川武志; 三竿貴彦; 高濱隆幸; 上田裕; 宮脇裕史  香川県医師会誌  64-  (特別)  61  -61  2011/09
• 約4年間,当院で経過観察された後に手術を行い,肺癌と確定診断された一例

  高塚萌; 益田智章; 青江基; 吉川武志; 三竿貴彦; 高濱隆幸; 上田裕; 宮脇裕史  香川県医師会誌  64-  (特別)  62  -62  2011/09
• 術前鑑別診断に難渋した肺原発MALTリンパ腫の1切除例

  吉田修; 青江基; 吉川武志; 三竿貴彦; 高濱隆幸; 上田裕; 宮脇裕史; 須崎規之  肺癌  51-  (4)  309  -309  2011/08
• 肺癌術後抗がん剤治療としてのTS‐1により出血性大腸炎を来したと考えられる1例

  青江基; 和唐正樹; 吉川武志; 三竿貴彦; 高濱隆幸; 上田裕; 宮脇裕史; 宇野浩司  肺癌  51-  (4)  302  -303  2011/08
• 低血糖による意識障害が診断の契機となったACTH分泌不全症の1例

  中村圭吾; 高濱隆幸; 馬場伸介; 秋山賢次; 和唐正樹; 高口浩一; 中田憲一  糖尿病  54-  (4)  319  -319  2011/04
• 腕神経叢発生の胸腔内神経鞘腫に対して胸腔鏡下手術を行った1症例

  高濱隆幸; 青江基; 伊賀徳周; 古川公之; 吉川武志; 三竿貴彦  日本呼吸器外科学会雑誌  24-  (3)  545  -545  2010/04
• 13. 不完全分煙オフィス内浮遊粉塵濃度について(一般演題,第50回中国四国産業衛生学会,地方会・研究会記録)

  須那 滋; 高濱 隆幸; 青木 つね子; 平尾 智広; 影山 浩; 鈴江 毅; 万波 俊文; 浅川 富美雪; 實成 文彦  産業衛生学雑誌  49-  (4)  145  -146  2007/07
• 15. 社内分煙の実態把握と改善の試み(一般演題,第50回中国四国産業衛生学会,地方会・研究会記録)

  青木 つね子; 影山 浩; 呉羽 晃徳; 大柳 直子; 見市 昇; 守安 秀行; 平尾 智広; 高濱 隆幸; 須那 滋; 浅川 冨美雪; 實成 文彦  産業衛生学雑誌  49-  (4)  146  -146  2007/07
• 不完全分煙オフィス内浮遊粉塵濃度について

  須那滋; 高濱隆幸; 青木つね子; 平尾智広; 影山浩; 鈴江毅; 万波俊文; 浅川富美雪; 實成文彦  産業衛生学雑誌  49-  (4)  145  -146  2007/07
• 社内分煙の実態把握と改善の試み

  青木つね子; 影山浩; 呉羽晃徳; 大柳直子; 見市昇; 守安秀行; 平尾智広; 高濱隆幸; 須那滋; 浅川冨美雪; 實成文彦  産業衛生学雑誌  49-  (4)  146  -146  2007/07
• Health examination in school

  JITSUNARI FUMIHIKO; SUZUE TAKESHI; TAKAHAMA TAKAYUKI  綜合臨床  55-  (5)  1449  -1457  2006/05

Awards & Honors

• 2020/09 Nara medical association Nara medical association Young Researcher's Award
  
• 2017/05 West Japan Oncology Group Ariyoshi/Fukuoka Prize
  

Research Grants & Projects

• Treatment response and prognosis prediction of immune checkpoint inhibitors by FDG-PET/CT: A Japanese multicenter prospective study

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

  Date (from‐to) : 2022/04 -2026/03 

  Author : 北島 一宏; 山門 亨一郎; 甲斐田 勇人; 大崎 洋充; 渡部 直史; 木島 貴志; 南 俊行; 高濱 隆幸
• Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.

  Japan Society for the Promotion of Science：Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

  Date (from‐to) : 2019/04 -2022/03 

  Author : HAYASHI Hidetoshi

   

  After approval of the research protocol by the institutional review board at multiple institutions, including Kinki University, registration of cases and collection of clinical information were conducted at each institution, and a total of 125 cases were registered from four institutions. Tumor tissue samples (FFPE) obtained by biopsy or surgery were collected from 90 of the registered cases, and RNA/DNA was extracted at our institution, and tumor immunity-related gene expression was evaluated using nCounter, PanCancer, and IO360 Panel. Part of the analysis is still in progress, and the final analysis is expected to include 60 patients. We found that response to combination therapy with immune checkpoint inhibitors and chemotherapy correlated with PD-L1 expression and some immune-related gene expression.

Committee Membership

• 2024/02 - Today   The Japanese society of medical oncology   Specialist committee
• 2023/12 - Today   International Association for the Study of Lung Cancer   The Global Multidisciplinary Practice Standards Committee (GMPSC)
• 2023/05 - Today   West Japan Oncology Group   Education and Public Relations Committee
• 2022/04 - Today   The Japanese Respiratory Society   Adult Pneumonia Practice Guideline 2022 Preparation Committee Member of the Systematic Review Committee
• 2019/07 - Today   Japanese Lung Cancer Society   Guidelines Review Committee Subcommittee on Guidelines for Patients
• 2022/03 -2024/02   Japan Society of Medical Oncology   Member of the Supervisory Medical Examination Section
• 2017/07 -2023/03   Ministry of Health, Labour and Welfare Commissioned Project for Training of Personnel Engaged in Genomic Medicine for Cancer Genomic Medicine Worker Training Committee

Other link

researchmap

https://researchmap.jp/takahama_t